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A Comparison of Quality of Life in Adult Patients with Heart Failure in Two Medical 
Settings: A Heart Failure Clinic and a Physician Practice. 
 
Janet Revay Bischof RN PhD  
 Heart Failure (HF), a major chronic disease that affects 4.8 million Americans, 
traditionally is managed by a primary care physician, with acute treatment at hospital 
emergency rooms often followed by inpatient admission. Ongoing support (prevention, 
diagnosis, treatment, intervention, symptom management, and end of life care), 
education, and intervention over the continuum are important to manage HF. The 
Modeling Role Modeling theory (Erickson, Tomlin, and Swain), is the study’s conceptual 
framework. When an individual knows about their illness, they mobilize internal/external 
resources to gain, maintain, or promote equilibrium. These resources affect daily 
activities. The purpose of this descriptive study is to compare perceptions of quality of 
life (QOL) in adult HF patients in two different settings: a HF clinic and physician 
practices. IRB approval was obtained. Inclusion criteria included adults ages 18 or 
older, HF diagnosis for greater than six months, current medical management of HF, 
ability to read/write English, and verbal validation of orientation to time, place, person. 
Quantitative analysis was conducted using SPSS and SF Health Outcomes Software. 
 Convenience samples were used. Subject age (n=60) ranged from 24 to 85 
years of age. Mean age in the HF clinic was lower (56.3) than the physician practice 
(72.9). In the total sample 41(68.3%) were male and 19(31.7%) were female. The 
majority of the sample 53 (68.3%) were white and seven (11.7%) were black (p=.044). 
There were no Asian or Hispanic subjects. 
The research questions that were addressed in this study are as follows: 
 1. Does health-related QOL differ among HF patients who are receiving medical 
care in two different clinical settings as measured by the SF-36v2 Health Survey using 
the Physical Component Scale (PCS) and the Mental Component Scale (MCS)? There 
was no significance difference found in the PCS score (p=.889) or the MCS score 
(p=.135). Of eight sub-scores only role-emotional showed significance (p=.007). 
 2. Does disease specific QOL differ among HF patients who are receiving 
medical care in two different clinical settings as measured by the Minnesota Living with 
Heart Failure Questionnaire (MLHFQ) total score, physical sub-score, and emotional 
sub-score? No significant differences in the MLHFQ total score (p=.907) with mean 
scores of two groups virtually equal, (HF clinic=46.4, physician office=47.2). The 
physical dimension sub-score was not different (p=.896). Mean sub-scores in the two 
groups were virtually equal, (HF Clinic=19.6, physician practice=19.3). The emotional 
dimension sub-score was not significant (p=.953)(HF Clinic=10.4, physician 
practice=10.5). There was no significant difference in disease specific QOL. 
 3. Are there differences in self care resources of HF patients that are receiving 
medical care in two different clinical settings as measured by the Self Care Resource 
Inventory and the Needs (SCRIN) and Availability (SCRIA) sub scores? Both the 
internal (p=.003) and external (p=<.001) SCRIN showed a significant difference. The 
external (p=.004) SCRIA showed a significant difference. 
Dissertation Advisor: Kathleen Sekula, PhD, APRN-BC 
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I. INTRODUCTION 
 
 A. Background of the Study 
 Advances in medical treatment of chronic diseases have led to the increase in 
the average age of the chronically ill patient and the quality of health care provided 
during the course of the disease. More than 90 million Americans live with some form of 
chronic disease which accounts for 70% of all deaths in the United States. The Center 
for Disease Control and Prevention broadly defines chronic disease as those illnesses 
that are prolonged, do not resolve spontaneously, and are rarely cured (Nordenfelt, 
1995). Common chronic diseases include arthritis, chronic obstructive lung disease, 
diabetes, epilepsy, and many cardiovascular diseases including heart failure (HF). The 
challenges and multiple uncertainties of adapting to chronic disease are profoundly 
personal and require frequent adjustments to management regimens (Landis, 1996; 
Rich, 2002). 
 People are living longer and the probability of developing a chronic disease 
increases with longevity. In 2000, people over the age of 65 represented nearly 13% of 
the population compared to 8% in 1950. Those who survive to age 70-75 can expect to 
live approximately 14 additional years; those who live to age 80-85 can expect to live 
approximately six more years (McKenna, 1994). 
 Increased access to medical interventions and medications has influenced the 
quality of health care available to the chronically ill population. Increased access to 
chronic disease care in the United States has increased the overall cost of chronic 
disease treatment. One major chronic disease is cardiovascular disease. The cost of all 
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types of cardiovascular disease in the United states in 2003 was estimated at $351.8 
billion (2006 Heart and Stroke Statistical Update, 2005). There are 21 million cases of 
cardiovascular disease reported annually with an estimated 725,000 deaths annually. 
Cardiovascular disease encompasses a number of cardiac diagnoses including 
cardiomyopathy, coronary artery disease, acute coronary syndrome (acute myocardial 
infarction), cerebrovascular accident, dysrhythmias, rheumatic heart disease, valvular 
heart disease, congenital defects, and HF (Heart disease, 2002). 
 Definitions of HF vary. HF is defined as a clinical syndrome or condition 
characterized by (1) signs and symptoms of intravascular and interstitial volume 
overload, which may include shortness of breath, crackles, and edema, or (2) 
manifestations of inadequate tissue perfusion, such as fatigue or poor exercise 
tolerance. These signs and symptoms result when the heart is unable to generate a 
cardiac output sufficient to meet the body's oxygen demands (AHCPR, 1994; Carelock 
& Clark, 2001). Professional organizations offer more complex definitions. The Heart 
Failure Society of American (HFSA) describes HF as a complex clinical syndrome with 
a complex pathophysiology that has multiple potential etiologies (Adams & Lindenfeld, 
2006). The American College of Cardiology (ACC) in conjunction with the American 
Heart Association (AHA) defines HF as a complex clinical syndrome that results from 
any structural or functional cardiac disorder that impairs the ability of the ventricle to fill 
with or eject blood (Hunt et al., 2005). This definition allows for HF to have a systolic 
and diastolic etiology. 
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 The etiology of systolic HF is contractile failure of the myocardium leading to 
reduced left ventricular end function. This can be due to coronary artery disease, 
ischemia, hypertension, metabolic disorders, or infection. It affects 50 to 60% of patients 
and is most common in men under the age of 65. The etiology of diastolic HF is left 
ventricular stiffness in which the ventricle does not fill at normal diastolic pressures. The 
ventricular muscle loses compliance and elasticity. It is most common in women over 
the age of 75 (Carelock & Clark, 2001). 
 HF pathophysiology is recognized clinically by a group of signs and symptoms 
produced by complex circulatory and neurohormonal responses to cardiac dysfunction. 
The hallmark clinical symptoms of HF are shortness of breath, fluid retention, and 
exercise intolerance (Adams, 1999). HF is a complex disease to manage in view of its 
multiple pathologies. Pathophysiologically, HF is characterized by structural remodeling 
and dilation of the left ventricular chamber, reduced myocyte shortening and wall 
motion, sodium retention, systemic vasoconstriction, impeded ventricular ejection, and 
neurohormonal activation (Adams, 1999). HF can develop in response to various 
diseases including myocardial ischemia, injury, necrosis, cardiomyopathy, or pulmonary 
disease. The major concern is that HF is often the end result of any cardiovascular 
disease. 
 There are many risk factors for developing HF which can include advancing age, 
left ventricular dysfunction, valvular heart disease, hypertension, diabetes, 
tobacco/alcohol abuse, obesity, high or low hematocrit, dysrhythmias, and genetic 
predisposition. Any of the listed risk factors in combination with the presence of 
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myocardial infection or myocardial infarction increases the risk of developing HF. The 
most common cause of HF in the elderly is coronary artery disease. Determining the 
cause of HF and correcting any underlying etiology is essential for long-term, effective 
disease management (Stanley, 1999). 
 The term HF is often used interchangeably with congestive heart failure (CHF), 
but HF is the more correct term as the symptom of pulmonary congestion may not 
always be present (Davis, 2002). In recent literature the abbreviation CHF is used to 
denote chronic heart failure. In the acute phase of HF, pulmonary congestion may be 
the presenting symptom. Symptoms can range from minimal shortness of breath to 
pulmonary edema requiring ventilatory support. In CHF, pulmonary congestion may be 
controlled and not in evidence. For the purposes of this research, the term HF will be 
used. 
 The New York Heart Association (NYHA) Classification System (classes I to IV) 
is commonly used to stage symptomatic HF (Table 1). First developed in the 1950's, it 
was updated in 1994 (Ganiats, Browner, & Dittrick, 1998). This classification system 
uses functional capacity to categorize severity of HF. It is a common subjective 
measurement reported in published cardiovascular and HF studies (Deaton, Exner, 
Schron, Riegel, & Prevost, 2001). Alternative words and classifications have been 
defined more recently to stress the evolution and progressive nature of HF (Caboral & 
Mitchell, 2003). The ACC/AHA task force identified four stages of HF, stages A through 
D (Table 1), which complements rather than replaces the NYHA classification system. 
The stages A through D target HF risk factors, screening, and treatment 
recommendations. 
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Table 1: Heart Failure Classification Systems 
NYHA1 
Classification2
NYHA Functional 
Description 
Alternative Heart 
Failure 
Classification3
ACC/AHA4 
Heart Failure 
Stages5
 
ACC/AHA 
Description 
Class I (Mild) Symptoms with more than 
ordinary activity 
Asymptomatic Stage A 
 
High risk for 
developing HF. No 
structural disorder 
of the heart 
  Asymptomatic Stage B Structural disorder 
of the heart 
present. Has never 
developed 
symptoms of HF 
Class II(Mild) Patient with slight, mild 
limitation of activity; they are 
comfortable with rest or with 
mild exertion. Ordinary 
physical activity results in 
fatigue, palpitation, or 
dyspnea. 
Asymptomatic Stage C High risk for 
developing HF. No 
structural disorder 
of the heart 
Class IIIa 
(Moderate) 
Patient with marked 
limitation of activity; they are 
comfortable only at rest; no 
dyspnea at rest 
Symptomatic Stage C  
Class IIIb 
(Moderate) 
Patient with marked 
limitation of activity; they are 
comfortable only at rest; 
recent dyspnea at rest 
Symptomatic 
with recent 
dyspnea at rest 
Stage C Past or present 
symptoms of HF. 
Associated with 
underlying 
structural heart 
disease 
Class IV 
(Severe) 
Patient who should be at 
complete rest; confined to 
bed or chair; any physical 
activity brings on discomfort 
and symptoms occur at rest. 
Symptoms of cardiac 
insufficiency at rest. 
Symptomatic 
with dyspnea at 
rest 
Stage D End-stage disease. 
Requires 
specialized 
treatment 
strategies 
1 NYHA New York Heart Association 
2 (Ganiats et al., 1998) 
3  (NYHA Heart Failure Classification, 2000) 
4  ACC/AHA American College of Cardiology/American Heart Association 
5 (Hunt et al., 2001) 
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Stages stress prevention through early recognition and timely treatment of HF, even 
prior to structural heart changes. 
This research utilized the NYHA Classification System when discussing stages of HF. 
  HF is a major chronic disease that is a burden on all aspects of the health care 
system. A decade ago, The National Heart, Lung, and Blood Institute  estimated that 
more than five million Americans have HF (Hunt et al., 2005). HF is a chronic disease of 
2,360,000 males and 2,440,000 females (2006 Heart and Stroke Statistical Update, 
2005) and each year there are approximately 550,000 new cases diagnosed. The 
annual incidence of HF approaches 10 per 1,000 individuals over the age of 65. It has 
been described as an epidemic increase (Barker, Mullooly, & Getchell, 2006). The 
incidence of HF is twice as common in individuals with a co-diagnosis of hypertension 
(stage I defined as a systolic blood pressure greater than 140 to 159 mm Hg and a 
diastolic blood pressure greater than 90 to 99 mm Hg) as compared to normotensive 
individuals (normal defined as a systolic blood pressure less than 120 mm Hg and a 
diastolic blood pressure less than 80 mm Hg) (Chobanian et al., 2003). The incidence of 
HF is five times more likely in individuals who have had a previous heart attack. About 
22% of male and 46% of female acute myocardial infarction (AMI) patients will be 
disabled with HF within six years (2006 Heart and Stroke Statistical Update, 2005). 
 Of the five million Americans with HF, about 1.4 million are under 60 years of 
age. HF is present in two percent of individuals ages 40 to 59, more than five percent in 
individuals ages 60 to 69, and 10 percent in individuals aged 70 or older. Among the 
black population the prevalence is greater (2006 Heart and Stroke Statistical Update, 
2005). The five-year mortality rate for HF is about 50%. From 1979 to 1999 HF deaths 
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increased by 14.5 percent. In 1993 there were 42,000 deaths where HF was identified 
as the primary cause of death and another 219,000 deaths where HF was listed as a 
secondary cause of death. If the patient is initially diagnosed as a Class IV HF, 70-95% 
of individuals die within the first year and 90% die in the second year of diagnosis. From 
1979 to 2001 HF deaths increased 155 percent (2006 Heart and Stroke Statistical 
Update, 2005). 
 From 1993 to 2003, deaths from HF increased 20.5 %. For the individual under 
the age of 65, 80% of men and 70% of women will die within eight years of a HF 
diagnosis. The survival rate for HF is about equal to the survival rate with most forms of 
cancer. In patients diagnosed with HF, sudden cardiac death occurs at 6-9 times the 
rate of the general population primarily due to lethal dysrhythmias (2006 Heart and 
Stroke Statistical Update, 2005). 
 For patients with cardiovascular disease, including all age groups, the top three 
reasons for hospitalizations are atherosclerosis, heart attack, and HF. Approximately 
80% of all emergency room visits for HF results in hospitalization. Hospital discharges 
with HF listed as the primary discharge diagnosis increased 159.4% from 1979 to 1998 
(438,000 males and 540,000 females). The number of patients with HF discharged in 
the United States rose from 377,000 in 1979 to 995,000 in 2001, an increase of 264 
percent (2006 Heart and Stroke Statistical Update, 2005). HF was listed as a secondary 
diagnosis in another 1.8 million hospital discharges. In 1999 there were 4.5 million 
hospital discharges for patients with cardiovascular disease with an average length of 
stay of 4.7 days (Heart disease, 2002). In 1998 this translated to $3.6 billion paid to 
Medicare beneficiaries for the treatment of HF or $5,471 per discharge. Published 
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hospital readmission rates within two days of discharge is two percent and that 
increases to 50% within six months of discharge (2006 Heart and Stroke Statistical 
Update, 2005). 
 Traditional medical management of the patient with HF is provided by a primary 
care physician and with urgent care of symptoms through treatment at local hospital 
emergency rooms followed by inpatient admission. While this remains a primary pattern 
for medical care, alternative settings for care are being used. Various settings 
collaborate to accommodate the entire continuum of care ranging from prevention, initial 
diagnosis, treatment/interventions, and emergency management of symptoms, and 
include the private physician office, disease specific clinics, outpatient clinics, hospitals, 
home health, and hospice (McCauley & Naylor, 2001). 
 The focus on disease management across the continuum is evident in the 
literature (Anderson, Pena, & Helms, 1998; Bertel & Conen, 1987; Bither & Apple, 2001; 
Fonarow, Creaser, & Livingston, 2001; Singh, 1995). The continuum includes 
prevention, diagnosis, treatment, intervention, symptom management, and end of life 
care. The provision of ongoing support, education, and intervention over the continuum 
of HF care is important to the management of the disease and its symptoms. Care can 
be provided to the patient with HF as a clinic outpatient, in the physician office, during 
emergency interventions or hospitalization, or in the home (Riegel & LePetri, 2001). 
 Starting in October of 2001, a national database was established to prospectively 
study characteristics, management, and outcomes in a broad sample of patients 
hospitalized with heart failure. The Acute Decompensated Heart Failure National 
Registry (ADHERE) is a multicenter registry with participation of more than 275 
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hospitals providing 100,000 patient cases. It is sponsored by Scios, Inc. and overseen 
by an independent scientific advisory committee of nationally recognized specialities. 
Patient eligibility is not linked to a specific therapeutic agent or regimen (ADHERE 
Registry, 2004). 
 The use of patient rated Quality of Life (QOL) tools as an outcome measure of 
chronic disease has been included in study designs with increasing frequency (al-
Kaade, 2001 ). QOL can be defined as an individual's satisfaction with his role at work, 
at home, and in his community (Bonomi, Patrick, Bushnell, & Martin, 2000; Dracup, 
Walden, Stevenson, & Brecht, 1992; Packa, 1989). QOL encompasses four major 
domains (physical/functional status, psychological status and well-being, social 
interaction, and economic/vocational status) and is measured by health related or 
disease specific QOL tools (al-Kaade & Hauptman, 2001; Cramer & Spilker, 1998). 
Health related QOL tools, such as the Short Form 36v2 Health Survey (SF-36v2), 
measure the above domains of QOL as it relates to an individual health perceptions 
(Cramer & Spilker, 1998). Disease specific QOL tools measure the above domains in 
relation to a specific disease condition. Illness and treatment affect QOL to the extent 
that they impact an individual's ability to independently perform the four domains 
satisfactorily. Clinicians and researchers have to consider QOL measures in assessing 
the effects of an illness and its treatment (Levine & Croog, 1985). As the population 
ages and chronic disease becomes even more prevalent in health care, measures of 
functional loss and disability assume greater importance in the assessment of both QOL 
and the cost-effectiveness of care (Kane, Rockwood, Finch, & Philp, 1997). 
 The delivery of medical and nursing care for the patient with HF affects not only 
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their acute and chronic care, but their day to day self care activities. Day to day 
activities such as bathing, cooking dinner, shopping, house cleaning, and driving are 
affected by chronic diseases such as HF. Self care resources are defined as internal 
and external resources that help an individual to maintain and promote an optimal level 
of well being (H. C. Erickson, Tomlin, & Swain, 1983). Examples of self care resources 
could include family support, friends, social support, financial assistance, hope for the 
future, control, or environmental conveniences (Baas, Trupp, & Abraham, 2001). Self 
care resources are identified by the individual patient and are given importance by the 
patient. Self care resources are used to cope with the stress of health care problems in 
daily life (Baas et al., 2001). 
 The financial consequence of chronic disease interventions and treatment on 
health care dollars is staggering. HF treatment has expanded to new and more complex 
interventions in order to manage the disease and symptoms and can increase the 
number of office visits, medications, surgical procedures, heart transplant candidates, or 
artificial heart implantation candidates. Total treatment costs for HF; including physician 
visits, drugs, and nursing home stays were more than $10 billion in 1990 (AHCPR, 
1994), $17.8 billion in 1993, and this cost continues to increase each year. HF costs in 
2004, both direct and indirect, were $28.8 billion (2006 Heart and Stroke Statistical 
Update, 2005). Visits to physician offices for HF increased from 1.7 million in 1980 to 
2.9 million in 1993. More than 65,000 individuals received home health care visits for 
HF each year . 
 Health care professionals and insurance companies closely manage the 
utilization of HF interventions. Although the treatments may be more expensive, the 
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treatments become more cost effective because of the decreasing length of stay of 
acute care hospital days and decreasing hospital readmission rates. (S. J. Bennett et 
al., 1999; Fonarow et al., 2001; "Here's how education saved $173,000," 1997; Mark, 
1997; McDonald et al., 2002; Polanczyk, Newton, Dec, & Di Salvo, 2001). With the 
improved access through alternative programs and new technology, correct utilization of 
interventions may end up saving the health care system dollars (Mark, 1997; Rector, 
2000).  
 B. Purpose of the Study 
 The purpose of this descriptive study was to compare quality of life in adult 
patients with HF in two different HF treatment settings: a disease specific HF clinic and 
physician run private practices. The data from the two samples is compared and 
contrasted. 
 C. Research Questions 
 The research questions that were addressed in this study are as follows: 
 1. Does health related QOL differ among patients with HF who are receiving 
medical outpatient care in two different clinical settings: a multi-disciplinary (nursing, 
medicine, pharmacy, physical therapy, social work, nutrition) disease specific HF clinic 
and physician run private practices as measured by the Medical Outcomes Study Short 
Form 36v2 Health Survey (SF-36v2) using the Physical Component Summary Scale 
and the Mental Component Summary Scale? 
 2. Does disease specific QOL differ among patients with HF who are receiving 
medical outpatient care in two different clinical settings: a multi-disciplinary (nursing, 
medicine, pharmacy, physical therapy, social work, nutrition) disease specific HF clinic 
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and physician run private practices as measured by the Minnesota Living with Heart 
Failure Questionnaire (MLHFQ) total score, physical sub-score, and emotional sub-
score? 
 3. Are there differences in self care resources of patients with HF that are 
receiving medical outpatient care in two different clinical settings: a multi-disciplinary 
(nursing, medicine, pharmacy, physical therapy, social work, nutrition) disease specific 
HF clinic and physician run private practices as measured by the Self Care Resource 
Inventory (SCRI) and the sub-scales Self Care Resource Inventory Needs (SCRIN) and 
Self Care Resource Inventory Availability (SCRIA) sub-scores? 
 D. Operational Definitions 
 Chronic Disease: Illnesses that are prolonged, do not resolve spontaneously, and 
are rarely cured (Nordenfelt, 1995). 
 Heart Failure: A cardiovascular clinical syndrome that has been diagnosed by a 
physician using a history of symptoms including shortness of breath and activity 
intolerance that has led to complex circulatory and neurohormonal responses causing 
cardiac systolic or diastolic dysfunction (Dracup et al., 1992; Funk, Milner, & Krumholz, 
2001) as measured by the NYHA HF Classification System (Ganiats et al., 1998). 
 Health Related Quality of Life: An individual's satisfaction with his role regarding 
health, physical functioning, psychological status, and social interaction at work, at 
home, and in the community (Grady et al., 1995; Packa, 1989) as measured by the SF-
36v2 sub-scores . 
 Disease Specific QOL: An individual with HF’s perceptions concerning the effects 
of HF on his life (work, home, and community) as measured by the MLHFQ total score, 
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physical and emotional dimension sub-scores (Rector, Kubo, & Cohn, 1987). 
 Disease Management HF Clinic: A designated clinic providing medical outpatient 
care with multidisciplinary health care personnel who have expertise in caring for 
patients with a specific diagnosis of HF (Fonarow et al., 2001). 
 Physician run private practice: A private physician practice that provides 
outpatient medical care to patients with varying cardiac diagnoses including HF. 
 Self-Reporting: Using a questionnaire format, the patient self-rates their 
responses to the questions without influence from other sources (Rector & Cohn, 1992). 
 Functional Status: Ability to perform activities of daily living as measured by the 
SF-36v2 (physical functioning sub-scale) and MLHFQ physical sub-scale (Ware, 
Kosinski, & Gandek, 2000). 
 Emotional Status: Perception of mental health and social functioning as 
measured by the SF-36v2 mental health sub-scale (Ware et al., 2000). 
 Self-Care Resources: The internal and external resources of a patient that are 
mobilized through self-care action to help gain, maintain, and promote an optimum level 
holistic health (H. C. Erickson et al., 1983).  
 E. Assumptions 
1. The medical outpatient settings provide the services that are needed to care 
for patients with HF. 
 2. Patients’ have the right to define their own QOL. 
 3. Patients’ have the ability to define their own QOL. 
 4. Patients’ will give honest answers to the questions. 
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 F. Conceptual Framework Overview 
 Of the many theories utilized in published QOL research, the Modeling Role 
Modeling (MRM) theory by Erickson, Tomlin, and Swain was chosen as a conceptual 
framework for this research. Developed and published in 1983 as Modeling and Role-
Modeling: A Theory and Paradigm for Nursing (H. C. Erickson et al., 1983), the intent 
was to develop a holistic nursing theory. Three health professionals worked on the 
development of the theory: Erickson, a registered nurse with varied experiences in 
nursing practice, education, and research; Tomlin, a registered nurse also with varied 
professional experiences in nursing practice and education; and Swain, a non-nurse 
with an educational background and with an expertise in psychology who has worked 
extensively with nursing colleagues in research and education (M. E. Erickson et al., 
1998). 
 In developing this holistic nursing theory, the authors were influenced by multiple 
theoretical works. The influences of Abraham Maslow, Erik Erikson, Jean Piaget, 
George Engle, Hans Selye, and Milton H. Erikson were integrated and synthesized into 
the model. Theories involving stress response were used by Erickson and Swain to lead 
to the development of the MRM theory of the Adaptive Potential Assessment Model 
(APAM) in 1976. Erickson, Tomlin, and Swain (1998) synthesized the work of Maslow 
into their MRM theory and used the Maslow hierarchy of needs to define nursing 
interventions in the nursing relationship. 
 The MRM theory also included input from the works of Winnicott, Lein, Mahler, 
and Bowlby. Their description of object attachment helped to define the concept of 
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affiliated-individuation. Affiliated-individuation is identified as the relationship between 
object attachment and need satisfaction. Affiliated-individuation is essential to need 
satisfaction, adaptive coping, and healthy growth and development. It explains the 
ability of the individual to mobilize resources when confronted with stressors such as 
loss, grief, or disease. (M. E. Erickson et al., 1998). 
 Other nursing theorists have also influenced the development of the MRM theory. 
Peplau in 1952 and Travelbee in 1966 identified the interpersonal process between the 
patient and the nurse which is significant in providing nursing care. Orem in 1959 
defined self care as the care which all persons require each day. The MRM theory uses 
the above concepts to address the patient self care resources that are available to 
assist  the individual in health and daily life activities. Orlando in 1961 identified that the 
aim of nursing was to provide assistance to meet the patient’s needs which ties in the 
concept of self care resources (H. C. Erickson et al., 1983). 
 The MRM theory identifies self-care as the individual’s knowledge, resources, 
and action. When the individual knows what has caused the stressor or illness, they can 
then mobilize the internal and external resources they will need to gain, maintain, or 
promote a level of equilibrium. The importance of self care and self care resources in 
the daily lives of patient with HF effects their daily activities. 
 Major Concepts and Definitions 
 The terms and concepts used within the MRM theory are:  
 Adaptation occurs as a client responds to stressors, both internal and external, to 
mobilize coping resources. Maladaptation occurs when a stressor taxes the individual’s 
energies and the person is unable to engage in constructive coping or mobilize 
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appropriate resources and results in biophysical vulnerability (H. C. Erickson et al., 
1983). 
 Holism implies that the whole is greater than the sum of the parts. Body, mind, 
emotion, and spirit are multiple subsystems that interact to affect and control the 
individual. Holism also encompasses both conscious and unconscious processes within 
this dynamic process (H. C. Erickson et al., 1983). 
 Affiliated Individuation is the ability to be dependent on support systems while at 
the same time maintain independence from those support systems which is referred to 
as the “I” and “we” states, the ability to be a part of and yet separate (H. C. Erickson et 
al., 1983). 
 Self-care is defined as the knowledge, resources, and actions to help the 
individual gain, maintain, and promote an optimal level of holistic health. Self-care 
resources are both internal and external. The nurse facilitates the individual in 
identifying and developing these resources (H. C. Erickson et al., 1983). 
 Nurturance assists the client in moving towards holistic health and is a cognitive, 
physiological, and affective process. Nurturance appreciates the value of the clients 
world from the client’s perspective (M. E. Erickson et al., 1998). It implies that the nurse 
seeks to know and understand the client’s personal model of his world (H. C. Erickson 
et al., 1983). 
 Facilitation is the role of the nurse when engaging or providing care to clients and 
is an interactive, interpersonal process which assists the individual to develop their own 
strengths. It allows the individual control or input into developing a plan of care and in 
decision making (H. C. Erickson et al., 1983). 
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 Unconditional acceptance is defined as being accepted as a unique, worthwhile, 
and important individual. The individual is accepted and respected as they are. This 
acceptance facilitates mobilization of resources and helps the individual to reach 
adaptive equilibrium (M. E. Erickson et al., 1998). 
 Nursing is defined as an interactive, holistic, interpersonal process with a goal for 
optimum health. In the MRM theory the nurse is a facilitator (M. E. Erickson et al., 
1998). 
 Modeling is the process the nurse uses to develop an image or understanding of 
the client’s world from the client’s perspective. There is an art and science to modeling.  
The nursing art is being able to mirror the client’s perspective of the situation. The 
nursing science is the scientific collection and analysis of data about the client’s world 
(M. E. Erickson et al., 1998). 
 Role-modeling is planning and implementing interventions that are unique for that 
client. It is the facilitation of the individual in attaining, maintaining, or promoting health. 
It is both an art and a science. Role-modeling becomes the essence of nurturance (H. 
C. Erickson et al., 1983). 
 Environment is not explicitly defined in the MRM theory, but is seen in the social 
subsystems within the theory. Those social subsystems would include the biophysical 
stressors which are part of the environment (M. E. Erickson et al., 1998). 
 Person is described as both a patient and client in the MRM theory. A patient is 
given treatment and instructions. A client participates in his own care and is a member 
of the decision making team. A client has some control over the planned regimen. The 
individual is also described in the theory as having likes and differences. Individuals are 
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alike in the need for affiliated-individuation, holism, and lifetime growth and 
development. Individuals are different in their need for endowment, adaption, and self-
care knowledge (M. E. Erickson et al., 1998). 
 Health is defined as a state of physical, mental, and social well-being, a state of 
dynamic equilibrium, not just the absence of disease. Dynamic equilibrium between 
various subsystems must be maintained (H. C. Erickson et al., 1983). 
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 II. REVIEW OF THE LITERATURE 
 Chapter II will present an overview of the heart failure (HF) literature. A review of 
health related and disease specific quality of life (QOL) literature will be reviewed as it 
relates to HF. Tools used to measure HF QOL will be reviewed. The study’s conceptual 
framework will be discussed and how it affects this research. 
 A. Heart Failure 
 Overview  
 The significance of a HF diagnosis is considerable. As more cardiac patients 
survive their initial event they can expect to live longer with cardiovascular disease. This   
longevity increases the opportunity for an individual to develop HF due to pathological 
changes within the cardiovascular system. The increasing elderly population will result 
in increasing numbers of HF patients regardless of trends in cardiac disease morbidity 
and mortality. From 1989 to 1999 the death rate from coronary artery disease 
decreased 24 percent and the actual number of deaths decreased 6.8 percent (2004 
Heart and Stroke Statistical Update, 2003). Complex therapeutic strategies are 
prescribed to manage HF symptoms which affect HF daily life. 
 Therapeutic strategies 
  Treatment strategies for the management of HF depend on the type of HF and 
underlying etiology. With the complex management of ongoing symptoms, vigilant, 
frequent monitoring is the key to maintaining optimum health. Treatment strategies for 
the management of HF could include all or a combination of the following: 
neurohormonal blockade, hemodynamic management, ensuring adequate myocardial 
perfusion/metabolism, maintenance of electrical stability, and lifestyle modifications 
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(Adams, 1999; Hunt et al., 2001). 
Neurohormonal blockade 
 The syndrome of HF affects the normal autonomic and hormonal responses by 
causing sympathetic overactivity and parasympathetic withdrawal (Burger & Aronson, 
2001). With the activation of vasoconstrictor systems (such as renin-angiotensin, 
vasopressin, and norepinephrine) in HF, a deleterious effect on heart rate and 
contractility is produced. There are four main pharmacologic avenues for 
neurohormonal blockade: angiotensin-converting enzyme (ACE) inhibitors, angiotensin 
II receptor blockers (ARB), aldosterone antagonists, and beta-blockers. 
 ACE inhibitors. Ace inhibitors are recommended for all patients with systolic HF 
to improve exercise tolerance, symptom relief, and reduction in mortality (Hunt et al., 
2001; Iwata et al., 2006). They suppress angiotension II and aldosterone production, 
decrease sympathetic nervous system stimulation, increase parasympathetic tone, 
decrease left ventricular filling pressures, and decrease systemic vascular resistence. 
The Assessment of Treatment with Lisinopril and Survival (ATLAS) trial concluded that 
if ACE inhibitors were used in patients with Class II - IV HF, it would save 100,000 lives, 
would prevent 250,000 hospitalizations, and reduce costs by $2 billion (Barcina 
Sanchez, Martin Cortes, & Fernandez Fernandez, 1995; Ess, Luscher, & Szucs, 2002; 
Richardson, Cockburn, & Cleland, 1999). These findings were also confirmed in the 
Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) trial when the 
addition of an ACE inhibitor (enalapril) was added to HF therapy (Pitt, 2000). There was 
a 16% reduction in mortality when enalapril was added to therapy in the Studies of Left 
Ventricular Dysfunction (SOLVD) trial. 
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 Angiotensin II receptor blockers (ARB). ARB’s block angiotensin II receptors 
(A-1 and A-2) at the cellular receptor sites and are often added to ACE inhibitor therapy 
or provide an alternative when the patient is ACE inhibitor intolerant (Eisenberg & Gioia, 
2006). The Valsartan Heart Failure (Val-HeFT) study (n=5,010) showed that the addition 
of valsartan was associated with a decrease in the need for hospitalization admission by 
27.5% and a decrease in mortality by 13.2% (Cohn & Tognoni, 2001). The Evaluation of 
Losartan in the Elderly (ELITE) study (n=3,152) also confirmed these statistics (Carson, 
2000). The Losartan Intervention for Endpoint reduction (LIFE) study (n=9,193) 
suggested that the efficacy of ARB’s in patients with HF remains unanswered (Massie, 
2002). 
 Aldosterone antagonists. Aldosterone antagonists, the most common of which 
is aldactone, have shown an increase in functional status, decrease in hospitalizations, 
and decrease in incidence of sudden death in patient with HF. The Randomized 
Spironolactone Evaluation study (RALES) used 25 mg per day of aldactone which 
allows it to compete with aldosterone in receptor sites and become cardioprotective 
(Bozkurt, Agoston, & Knowlton, 2003). The RALES trial (n=104) was stopped early 
when an interim analysis showed a 30% reduction in the risk of death and a 30% 
reduction in hospitalization for cardiac causes. 
 Beta Blockers. Beta blockers should be utilized in patients with systolic HF 
(Adams, 1999). This therapy has been advocated for patients with HF since the 1970's, 
but did not become common practice as an intervention until the past few years. Beta 
blockade improves myocardial function, prolongs survival, and prevents serious 
dysrhythmias (Foody, Farrell, & Krumholz, 2002). Both the HFSA (Adams, 1999) and 
  
22
the ACC/AHA guidelines recommend the use of beta blockers in all stages/classification 
of HF and for those at risk for developing HF (Chizzola et al., 2006; Hunt et al., 2001). 
This recommendation is supported by the Carvedilol Prospective Randomized 
Cumulative Survival Trial (COPERNICUS) (Packer, Coats, & M.B., 2001), the Beta-
Blocker Evaluation of Survival Trial (BEST) (Bristow, Shakar, Linseman, & Lowes, 
2001) and the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure 
(MERIT-HR)trial (Goldstein & Hjalmarson, 1999). These trials were associated with a 
consistent 40% reduction in hospitalizations and a 30% reduction in mortality (Foody et 
al., 2002). It has also been shown that adding carvedilol to existing HF treatment can 
reverse the remodeling of the cardiac sympathetic nervous system function (Chizzola et 
al., 2006). 
 Newer neurohormonal interventions are on the horizon. Vasopeptidase Inhibitors 
(VPI) are currently in trial (Dawson & Struthers, 2002; Quaschning et al., 2001). They 
reduce vasoconstriction, increase the body’s vasodilator substances, inhibit ACE, and 
inhibit neutral endopeptidase. In theory, these drugs should be beneficial in both 
hypertension and HF. Efficacy in hypertension has been demonstrated, but the role in 
HF remains unclear. Preliminary results from the Omapatrilat Versus Enalapril 
Randomised Trial of Utility in Reducing Events (OVERTURE) fail to establish VPI as a 
first line therapy in HF (Dawson & Struthers, 2002). 
 Cytokine antogonists control the inflammatory response in the endothelial layer 
of muscle. Many of the inflammatory cytokines have the potential to negatively influence 
heart contractility, induce hypertrophy, and promote apoptosis thereby contributing to 
the cardiac remodeling process in HF (Gullestad & Aukrust, 2001). 
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 Use of intravenous immunoglobulin in one small study enhanced left ventricular 
ejection fraction in patients with HF which did correlate with the anti-inflammatory 
effects of the therapy (Aukrust, Damas, & Gullestad, 2003). Further research will be 
needed to identify if this therapy will be beneficial to large numbers of HF patients . 
Hemodynamic management 
 Hemodynamic management provides for the lowest systolic blood pressure that 
allows cerebration, ambulation, and urination. This involves preload reduction (diuretics, 
venodilators), afterload reduction (ACE inhibitors, Nipride, hydralazine, isororbide), and 
adequate fluid status. Inotropic support with the use of digoxin provides for symptom 
improvement (Davis, 2002). 
 Diuretics are frequently required to treat fluid retention in patients with HF 
(Costello-Boerrigter et al., 2006). Through their effects on sodium and water balance, 
diuretics decrease blood volume and venous pressure. Diuretic classes commonly 
include loop diuretics, thiazide diuretics, and potassium-sparing diuretics. 
 While the monitoring of hemodynamic status in acute care patients is common 
place, new technology is allowing for monitoring of patients in the outpatient setting. 
Using an implantable hemodynamic monitor (IHM), heart rate, activity, right ventricular 
systolic pressure, right ventricular diastolic pressure, and estimated pulmonary artery 
diastolic pressures are continuously monitored (Adamson et al., 2003; Magalski et al., 
2002; Mehra, 2006; Ohlsson et al., 2001). The measurements obtained are useful in 
day to day clinical monitoring of HF patients to proactively intervene with appropriate 
interventions in a timely manner. 
 Digoxin provides inotropic support. Digoxin is added to the medication regimen 
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after ACE inhibitors, beta blockers, and diuretics are in use and the patient remains 
symptomatic. It is also used in patients with atrial fibrillation to slow the heart rate 
(Ammon, 2001). Digoxin increases myocardial contractility by inhibiting sodium-
potassium adenosine triphosphatase and sensitizes cardiac baroreceptors to reduce 
sympathetic stimulation from the central nervous system (Davis, 2002). Other inotropic 
agents used include dopamine, dobutamine, and milrinone. Long term outpatient use of 
dopamine and dobutamine remains controversial (Hunt et al., 2001). While it does seem 
that pharmacological therapy can improve symptoms and improve quality of life, 
especially in the home setting, concern about increased mortality remains (Kellum, 
2001). 
 Nesiritide is a human B-type natriuretic peptide and is manufactured from 
escherichia coli using recombinant DNA technology. Approved by the Federal Drug 
Administration in 2001, it is the first in a new class of drugs. Nesiritide is the same as 
the endogenous peptide produced by the ventricular myocardium as a result of volume 
expansions and pressure overload (Colbert & Greene, 2003). The Vasodilation in the 
Management of Acute Congestive Heart Failure (VMAC) study was a ramdomized, 
double-blind trials of subjects (n=489) with dyspnea at rest that showed that short-term 
intravenous infusion of nesiritide is associated with hemodynamic and symptomatic 
improvements in patients with acutely decompensated HF (Keating & Goa, 2003). 
Adequate myocardial perfusion and metabolism 
 Adequate myocardial perfusion and metabolism can be accomplished through 
circulatory assist devices or surgical options. Circulatory assist devices support the 
circulation when the injured myocardium cannot generate adequate cardiac output. 
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They decrease the left ventricular workload and enhance oxygen supply to the 
myocardium (Oz, 2001). Devices could include intra-aortic balloon pump (IABP) or 
ventricular assist devices (VADS). VADS are a bridge to transplant, but are now being 
trialed as a bridge to recovery (short term therapy), bridge to bridge (short term to allow 
for implantation of a long term device), or as destination therapy (VADS as an implanted 
device instead of cardiac transplant) (Oz, 2001; Smart & Palanichamy, 2005). The 
Randomized Evaluation of Mechanical Assistance for the Therapy of Congestive Heart 
Failure (REMATCH) study showed that VADs can prolong life and improve the quality of 
life in a patient group awaiting transplant (Rosen, Contrada, Gorkin, & Kostis, 1997). 
 There are various surgical options for improving cardiac function in the patient 
with HF with or without heart replacement. Coronary artery bypass grafting (CABG) is 
used to improve vascularization of the cardiac muscle in patients with reversible 
ischemic myocardial defects. CABG is needed when restoration of coronary blood flow 
is necessary. Approximately 500,000 CABG procedures are done annually and 50% of 
patients have Class III or IV HF. Several studies show good long term survival in the 
use of CABG to improve outcomes in patients with HF (Baron et al., 2002; Elefteriades 
& Edwards, 2002; Miller, 1993). 
 Mitral valve reconstruction to correct mitral valve regurgitation is another surgical 
procedure for patients with HF. Mitral valve regurgitation leads to progressive left 
ventricular dysfunction and volume overload of the left ventricle. It also increases the 
severity of HF and increases the risk of clot formation (due to blood stasis in the left 
atrium and ineffective emptying of the left ventricle) which further complicates the 
treatment regime. Mitral valve replacement or reconstruction is often performed in 
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conjunction with CABG when mitral value regurgitation is significant. While valve 
reconstruction procedures in the patient with HF have traditionally been avoided due to 
a higher mortality rate, newer studies are showing improved functional status and NYHA 
functional class improvement (Bolling, Smolens, & Pagani, 2001). 
 Surgical procedures such as the Batista (Abe, Fukada, & Morishita, 2001; 
Blanche, Frota Filho, Trento, & Lucchese, 1998; Bridges & Bogen, 2001) and Dor (Di 
Donato et al., 2001; Dor, 2001) procedures have also been developed to improve 
outcomes in HF. The Batista Procedure, or partial left ventriculectomy, is a heart 
reduction surgery developed by a Brazilian surgeon, Dr. Randis Batista. Heart muscle is 
cut out using a linear incision in an attempt to return the ventricle to optimal size and 
function by changing geometry. Many of the studies indicate the use of this procedure 
for bridge to transplant or for those patients for whom transplant is either cost prohibitive 
or unavailable (Abe et al., 2001; Bolling et al., 2001; Bridges & Bogen, 2001; Brouwer et 
al., 1999; Garcia, Barril, Manapat, Lopez, & Luna, 1999; Sankar, Baruah, Ninan, Rajan, 
& Cherian, 2001). 
 The Dor Procedure or endoventricular circular patch plasty has been used to 
excise ventricular aneurysms and improve ventricular shape. Studies have shown 
improved systolic function post procedure (Di Donato et al., 2001; Dor, 2001). Both the 
Batista and Dor procedures remain controversial (Abe et al., 2001; Moreira & Noedir, 
2001). Overall, outcomes have been less than desirable and these procedures are 
rarely done today. 
 Cardiac transplantation is the gold standard to resolve the physiological changes 
in the patient with HF (Zeltsman & Acker, 2002). There are 50,000 Americans who need 
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a new heart transplanted for a variety of diseases, and 95% will die without getting the 
transplant. There are approximately 7,700 names on the transplant list. It is available to 
only a small number of patients (Baas, Fontana, & Bhat, 1997; El-Zaru & DeNofrio, 
2002). The cost of cardiac transplantation versus VADS is about the same, $100,000 to 
$125,000. Current estimations of a 10 year survival rate of 50% remains superior to all 
available mechanical devices (Haverich & Gorler, 2002). Recipient selection is key to 
maintaining survival rates (Deng, Smits, & Packer, 2002; Gradaus et al., 2002; Tsai et 
al., 2002). Follow up post transplant including medications adds an additional $10-
18,000 per year. 
 Newer state of the art technology to improve myocardial perfusion and 
metabolism are being investigated. Angiogenesis, using vascular endothelial growth 
factor and fibroblast growth factor to produce new growth of coronary blood vessels, is 
being trialed. In animal and human trails, several compounds are showing promise.  
Prostaglandin E is a potent vasodilator and induces angiogenesis in animal tissue 
(Mehrabi et al., 2001). Gene transfer using vascular endothelial growth factor to 
stimulate angiogenesis and improve perfusion is being used on ischemic myocardium 
(Lathi et al., 2001). Use of human hepatocyte growth factor combined with cellular 
cardiomyoplasty is being tested in rats and hamsters as a possible strategy for the 
treatment of HF (Miyagawa et al., 2002; Taniyama et al., 2002). Other types of cell 
transplantation are being considered with potential yet to be determined in the treatment 
of HF (Ahmedzai, 1995). The investigation into the use of both embryonic stem cells 
and adult somatic stem cells to augment myocardial performance is ongoing (Hughes, 
2002). 
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Maintenance of electrical stability 
 Sudden death due to dysrhythmias in HF is 6-9 times the rate of the general 
population (2004 Heart and Stroke Statistical Update, 2003). Dysrhythmias can include 
tachy dysrhythmias, brady dysrhythmias, pulseless electrical activity, or ventricular 
dysrhythmias. Predisposing factors that contribute to the development of electrical 
instability can include electrolyte imbalance, myocardial tissue changes, ischemia, 
sympathetic nervous system activity, and other therapeutic interventions (beta 
blockers). The decision to treat the dysrhythmia is based on the answer to the question 
“Is the patient symptomatic?” Treatment options can include electrical cardioversion, 
pharmacologic interventions, revascularization, ablation, internal cardiac defibrillator 
(ICD), or biventricular pacing. The Multicenter InSync Randomized Clinical Evaluation 
(MIRACLE) (Saxon, 2002) study looked at biventricular pacemaker devices with and 
without ICD. This study showed reversal of ventricular remodeling in those patients with 
successful implant which could affect the overall long term effects of HF on the ventricle 
over time. 
Lifestyle modifications 
 Life style modifications are aimed at improving oxygen consumption in HF 
patients. Extensive patient education and close follow-up is provided which often 
includes a combination of exercise, sleep enhancement, and dietary modifications. 
 Through exercise training, peak oxygen consumption can be improved. Neither 
the amount of exercise necessary to produce functional improvement nor the best 
training strategy has yet to be defined (Uretsky et al., 1998). Rehabilitation exercise 
programs focus on both aerobic and strength training. Although the Agency for Health 
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Care Policy and Research in 1994 recommended cardiac rehabilitation guidelines and 
exercise therapy for HF patients, insurance reimbursement has not materialized due to 
the resulting increase in cost (AHCPR, 1994). With a low level exercise program, 
benefits are seen within the first four months. The individual must continue to exercise 
to maintain the benefits, but after four months there is usually no further improvement 
(Uretsky et al., 1998). 
 Improvement of sleep patterns in patients with HF improves oxygenation and 
lifestyle. An improvement in left ventricular ejection fraction is noted with the use of 
continuous positive airway pressure (CPAP). Problems common with the patient with 
HF are sleep apnea (Javaheri, 2006), snoring, and daytime sleepiness, often in 
conjunction with overwhelming fatigue. Administration of diuretics at night may also 
disrupt sleep patterns and timing may need to be adjusted (S. J. Bennett, Cordes, 
Westmoreland, Castro, & Donnelly, 2000). The fear of ‘not waking up’ in the morning 
disrupts nightly sleep patterns (S. J. Bennett et al., 2000). 
 Guidelines regarding sodium restriction in the diet of patients with HF are well 
documented (Volpe et al., 1993). Due to the inability of the body to excrete sodium, 
sodium is retained thereby retaining fluid. The degree of sodium restriction is less clear, 
ranging from a two gram sodium or less diet to no added salt in cooking. The dosage of 
diuretics usually increases as the sodium restriction decreases (Dracup et al., 1994; 
Uretsky et al., 1998). While patients report that adherence to the diet lessens 
symptoms, most report difficulties in maintaining the diet. 
 Body, mind, spirit connections and interventions are also used. Emotions such as 
depression, hostility, anxiety, anger, and hopelessness play an important part in the 
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daily life of the patient with HF (S. J. Bennett et al., 2000). While the use of professional 
therapists has been suggested in the literature, the inclusion of professional therapists 
as part of the interdisciplinary team has not been widely reported (Bither & Apple, 2001; 
Uretsky et al., 1998). The use of HF support groups led by physicians and nurses were 
evident in the literature (S. J. Bennett, Pressler, Hays, Firestine, & Huster, 1997; Rich et 
al., 1995). 
 The term counseling was used interchangeably with patient 
information/education (Bours, Ketelaars, Frederiks, Abu-Saad, & Wouters, 1998; 
Dracup et al., 1994; Uretsky et al., 1998). Research has focused on the reporting of 
physical symptoms and self-management techniques. The negative emotional 
symptoms are just as important in looking at the patient with HF holistically (S. J. 
Bennett et al., 2000). 
 Patient education is a key component in implementing lifestyle modifications for 
the patient with HF (Michalsen, Konig, & Thimme, 1998; Rich et al., 1995). Inclusion of 
the family or significant others can also greatly influence the implementation of patient 
education strategies (Uretsky et al., 1998). Adherence may fail due to multiple reasons: 
patients do not understand how to integrate the information into their activities of daily 
living, they may forget the instructions, they may not be convinced that the strategies 
will improve their symptoms, or the interventions prescribed may not be followed due to 
their burden on family finances (Dracup et al., 1994; Michalsen et al., 1998). 
Preventative Care 
 The HF literature is just starting to focus on the prevention of HF rather than the 
management of HF. Primary prevention is based on the identification of HF risk factors 
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such as hypertension and cardiovascular disease, and the development and 
implementation of patient specific strategies to decrease their effect on the individual’s 
overall health (Logeart, Guiti, Ennezat, & Cohen-Solal, 1998). Primary care providers, 
especially nurses, play an important role in HF prevention when they perform routine 
medical check-ups and health education (D. W. Baker, 2002). 
 The importance of wellness education is an example of how the nurse can help 
to delay the onset of HF. Cardiovascular risk factors (hypertension, myocardial 
ischemia, obesity, diabetes) that are addressed early or prior to a diagnosis of HF can 
affect the spread of this chronic disease. By changing the HF paradigm to include 
prevention, health care professionals can truly care for the patient across the continuum 
(Francis, 2000). Addressing the Stage A patient with HF (Table 1) risk factors, as well 
as coronary artery disease risk factors, is the first important step in preventing HF 
(Caboral & Mitchell, 2003). 
 B. Treatment Locations 
 There are multiple treatment locations that can be used by the patient for the 
treatment of HF. The emergency department is a frequent location for initial treatment of 
decompensated HF and is usually followed by acute care hospital admission (Butler et 
al., 2006). The development of observation units in the emergency department is a new, 
temporary treatment location (Peacock, Young, Collins, Diercks, & Emerman, 2006). 
 The two major health care settings in which long-term patients with HF are 
treated are the physician office and disease specific HF clinics. The primary treatment 
location of the physician office to provide care for the patient with HF has been 
expanded in recent years. New and diverse treatment providers which include HF 
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clinics, telephone monitoring, case management, home health, and hospice are 
instrumental in treating and caring for the patient with HF. The medical model of disease 
management of HF patient care has been expanded. Treatment for HF is an evolving 
plan that can change from day to day, week to week, and month to month. To maintain 
a level of wellness the patient with HF and family require intense education, monitoring, 
and follow-up. Research is now showing the financial benefits of multidisciplinary HF 
care over the traditional disease management model (McDonald et al., 2002). The 
disease management model is a vague term which deals with acute illness and 
physician directed care (Havranek, Masoudi, Rumsfeld, & Steiner, 2003). 
 The physician office has been the primary site for care of the patient with chronic 
disease. Face to face physician visits are based on current problems and symptoms 
reported by the patient. Visits are scheduled based on the practitioner’s judgment. 
Patients with chronic illnesses, like HF, have infrequent physician contact. In the 
literature it is reported that patients see a physician on the average of once a month for 
15 minutes. The patient is on their own the remainder of the time (Rich, 2002). Another 
report sets the average at 15 minutes in a physician office every six months (Bertel & 
Conen, 1987). This time frame does not facilitate the needed individualized interaction 
and intervention adjustment needed to optimally manage the HF population. 
 Using a multidisciplinary approach to HF management allows for discipline 
expertise to improve the overall patient outcomes (Fonarow et al., 1997; Fourny, 
Neuder, Tranchant, & Francois, 2006; Hanumanthu, Butler, Chomsky, Davis, & Wilson, 
1997; Rich, 1999; Ventura, Smart, & Loyalka, 2000). The multidisciplinary team consists 
of physicians, nurse practitioners, social workers, dietitians, home health nurses, 
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occupational and physical therapists, pharmacists, and case managers. The medical 
management of HF involves the prescribing of medications, interventions, and follow-up 
of existing co-morbidities. Financial counseling is integrated into defining existing and 
potential resources. Patient and family education is provided to integrate the medication 
and intervention regimen into daily life routines. (Rich, 1999; Ventura et al., 2000). 
 HF clinics in various forms are becoming the primary multidisciplinary form of 
delivering HF care. They exist in several formats: community hospital based, free 
standing, nurse managed, physician managed, teaching hospital based, and integrated 
in other disease outpatient clinics (Akosah, Moncher, Schaper, Havlik, & Devine, 2001; 
Hershberger et al., 2001; McMurray & Stewart, 1998; Paul, 2000; Pitt & Nicklas, 2000; 
Stromberg, 1998). While standardization of resources (available health care 
professionals, services provided, interventions provided) in HF clinics vary from clinic to 
clinic (Riegel & LePetri, 2001), there is proven financial and emotional benefit to the 
individualized care and follow-up (Akosah et al., 2001; Hershberger et al., 2001; 
McDonald et al., 2002; Paul, 2000). 
 Common resources that could be available in the clinic setting include access to 
physicians, cardiologists, registered nurses, pharmacists, dieticians, home health 
nurses, occupational and physical therapists, cardiac rehabilitation personnel, and 
social workers. While some resources vary from program to program, there are certain 
features and activities that are common to most programs. Essentials would include a 
case manager or coordinator, patient education activities, enhancement of patient self-
management skills, optimization of medications, and close follow up (Rich, 2002). The 
goals of any HF clinic would be to optimize clinical and economic management of the 
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patient with HF (Paul, 2000). The HF clinic model attempts to move HF management 
from reactive care to proactive care (Hershberger et al., 2001). 
 Case management models have been used in both the inpatient and outpatient 
HF settings. There is a focus on patient progress toward specific outcomes with 
subsequent modifications in care based on the evaluation of patient improvement. This 
standardization of expectations of patient progress prepares the patient for timely 
discharge while keeping resource use at acceptable and appropriate levels (Lynn & 
Kelley, 1997). 
 Community based home monitoring models are also being implemented. Patient 
data is obtained daily by the patient at home (weight, vital signs, and symptoms such as 
shortness of breath, fatigue) and entered into a data system via phone or computer 
(Heidenreich, Ruggerio, & Massie, 1999). Telephone monitoring consists of practitioner 
initiated calls or call-in systems for patients and care givers. Phone calls are used as 
adjunct visits in between face to face visits (Shah, Der, Ruggerio, Heidenreich, & 
Massie, 1998). Use of home health visits as the face to face visits are also utilized, but 
the number of insurance covered visits may be limited. 
 Hospice interventions for the patient with HF are mainly for palliative care and 
symptom management. The hospice care concept was established in London, England 
in 1968 to improve the QOL of the terminally ill. Care focuses on symptom control 
(Masters & Shontz, 1989). Criteria for hospice is a NYHA Class IV designation and a 
prognosis of less than six months. 
 C. Quality of Life 
 The definition of QOL in the literature varies. Researchers define QOL using 
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concepts such as well-being (Dracup et al., 1992), overall physical and psychological 
well being (Rideout, 1992), or satisfaction with life in general (Riedinger, Dracup, & 
Brecht, 2002). Studies dealing with chronic disease including HF include QOL 
measurements in combination with physiological measurements to measure patient  
outcomes change. When studies regarding treatments, interventions, or medications 
are developed, the outcomes studied include both the physiological measures as well 
as their effect on life (S. J. Bennett & Pressler, 1995). 
 The use of various tools to measure QOL is addressed in the literature. Many  
QOL tools focus on functional ability in terms of activity and have not taken into account 
other dimensions of QOL (Jalowiec, 1990). A more comprehensive QOL tool 
encompasses physical, psychological, and the social aspects of a person’s life. Studies 
that integrate physiological and QOL measurements to show benefit from an 
intervention are more commonplace in current research. 
 The subjectivity of the QOL measurement has been questioned when earlier 
tools were completed by the health care professional about the patient’s QOL rather 
than by self-report of the patient. The increasing role of the patient participating in health 
care decision making enabled the patient evaluated QOL score to be a truer indication 
of patient perception based on their individual social, home, work, and health status 
(Christ & Siegel, 1990). Work on The effect of treatments such as chemotherapy, 
radiation therapy, and radical surgeries on activities of daily living was studied. Some of 
the earliest integration of QOL studies with treatment regimens were with cancer 
patients (Ganz, 1994). 
 Global QOL measurements, also called health related QOL, are used to measure 
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satisfaction or dissatisfaction with life in general. QOL is an individual's satisfaction with 
his role regarding health, physical functioning, psychological status, and social 
interaction at work, at home, and in the community (Grady et al., 1995; Packa, 1989). 
Their use in diverse populations gives an overall measure of satisfaction with their QOL 
(Ormel, Lindenberg, Steverink, & Vonkorff, 1997).  
 Disease specific QOL tools have been developed with questions specific to a 
particular chronic disease (Moy, Ingenito, Mentzer, Evans, & Reilly, 1999; O'Conor, 
Johannesson, Hass, & Kobelt-Nguyen, 1998 ; Plaza, Serra-Batlles, Ferrer, & Morejon, 
2000; Rector & Venus, 1999). Disease specific tools address the quality of activities of 
daily living in patients with diabetes, arthritis, pulmonary disease, and cancer. They 
measure an individual's perceptions concerning the effects of HF or any chronic disease 
on their life at work, at home, and in the community (Rector, Kubo et al., 1987). 
 There have been several tools developed for or used in the HF population. The 
Short Form-36v2 Health Survey (SF-36v2) was developed as a health related QOL tool 
and has been used in the HF population. The Minnesota Living with Health Failure 
Questionnaire (MLHFQ) was one of the first HF disease specific tools developed 
(Rector, Frances, & Cohn, 1987) and is frequently used in the HF population. The 
Kansas City Cardiomyopathy Questionnaire (KCCQ) (Green, Porter, Bresnahan, & 
Spertus, 2000) is one of the newest tools developed to quantify health status and QOL 
in HF patients. The KCCQ is a new, self-administered, 23-item questionnaire that 
quantifies physical limitations, symptoms, self-efficacy, social interference and QOL. It 
was administered with the Short Form-36 (SF-36) and MLHFQ. The researcher felt that 
the sensitivity of the new questionnaire was substantially greater than that of the 
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MLHFQ or the SF-36 (Green et al., 2000). However, the KCCQ tool was not selected for 
this research because of minimal published studies in the literature and the 
predominance of the MLHFQ in HF studies. 
 The Self-Management of HF Questionnaire was developed to evaluate self-
management of HF (Riegel, Carlson, & Glaser, 2000). Face and content validity of the 
tool were demonstrated adequately with internal consistency scores of the six sub-
scales of the instrument ranged from .79 (measured ease of evaluating treatment) to .92 
(evaluating the change over time). Reliability could not be calculated for one sub-scale 
(evaluating the treatment) because of missing data that resulted from patients skipping 
sections because they had not experienced a symptom.  
 The tools chosen for this research are the MLHFQ, the SF-36v2, and the Self 
Care Resource Inventory (SCRI). The literature will be reviewed from the standpoint of 
overall information, clinical research, and patient populations. 
Minnesota Living with Heart Failure Questionnaire 
 The MLHFQ was developed in 1986 (Appendix A). It is a 21-item questionnaire 
with a Likert rating scale of 0 - 5 (6 point response range) extending from ratings 
defined as no, very little, to very much. A total possible score of 0 to 105 is obtained 
with physical and emotional sub-scores. The MLHFQ tool is a commonly employed 
disease specific health status measure for HF (Green et al., 2000). 
 The MLHFQ instrument was designed for use as a self reporting tool with 
patients with HF and has been used extensively with this population over the past 10 
years. Rector and Cohn (1992) conducted a randomized, double-blind, placebo-
controlled clinical trial of pimobendan to measure patient outcomes using the MLHFQ. 
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As a disease specific tool that measures QOL for the HF population, the MLHFQ has 
been reported to be valid, reliable, and effective (Cohen-Solal, Caviezel, Laperche, & 
Gourgon, 1994; Green et al., 2000; Guyatt, 1993). This tool will be used to collect HF 
disease specific QOL information and patient perceptions in this study. 
 Questions focus on impairments that patients frequently attribute to the diagnosis 
and symptomatology of HF, and evaluates the patient’s perceptions of the effect of HF 
treatments. It does not represent all facets of life that can be affected by the chronic 
disease of HF. The self-report questionnaire is completed by the patient rather than a 
health care provider and the patient rates the presence or absence of therapeutic 
benefit. When health care providers rate QOL or therapeutic benefit, the scores do not 
always agree with the perceptions of the patient (Rector & Cohn, 1992). 
 The MLHFQ was compared to the NYHA Functional Classification System for HF 
(Dracup et al., 1992). In the development of the MLHFQ a comparison with the NYHA 
classification was done with 83 patients. A correlation of .80, p<0.01 was established. 
(Guyatt, 1993). As a disease specific tool that measures QOL for the HF population, it 
has been shown to be valid, reliable, and effective. (Berry & McMurray, 1999; Cohen-
Solal et al., 1994; Guyatt, 1993; Havranek et al., 1999; Shively, Fox, & Brass-Mynderse, 
1996). It has been used extensively in medication research with patients with HF. 
 Research was conducted regarding the addition of the drug flosequinan to the 
therapeutic regimen for patients with HF (n=322) currently on a diuretic, digoxin, and an 
ACE inhibitor (Massie et al., 1993). Efficacy was evaluated with serial measurements of 
treadmill exercise time, responses to the MLHFQ, and clinical assessments during a 
baseline phase and a 16-week treatment period. Results showed that the addition of 
  
39
flosequinan 100 mg once daily improved the overall MLHFQ score significantly when 
compared with placebo. 
 The physiologic effects of ACE inhibitors was studied to determine if their effects, 
in conjunction with all other aspects of ACE inhibitor treatment, favorably alter QOL as 
judged by the patients (Rector, 1995). The available data suggest that symptomatic 
patients who have a limited QOL of life can be improved by ACE inhibitors. The 
research also showed that it was reasonable to assume that avoidance of episodes of 
decompensated HF and ischemic events would have some yet-to-be-defined effect on 
maintenance of patients' QOL. 
 A randomized, double-blind crossover study design (n=15) was used to 
determine whether supplemental oral L-arginine can augment peripheral blood flow and 
improve functional status in patients with moderate to severe HF (Rector et al., 1996). 
Subjects were given six weeks of oral L-arginine hydrochloride and six weeks of 
matched placebo capsules in random sequence. With the 15 patients in the study, 
results showed lower physical sub scores on the MLHFQ. Supplemental oral L-arginine 
had beneficial effects in patients with HF. 
 A quinolone inotropic agent (OPC-8212) was studied in 17 patients with 
moderate to severe HF (Kubo, Rector, Strobeck, & Cohn, 1988). The MLHFQ was 
administered prior to and after one month of treatment. The MLHFQ scores showed 
patients reported an improvement in total scores (49 to 38, respectively with p <.05) in 
daily functioning. 
 The MLHFQ has also been used to study the effects of severity of HF symptoms 
in relation to HF interventions. The relationship between exertional symptoms, 
  
40
ventilatory and skeletal muscle dysfunction, and circulatory function in patients with HF 
was studied in 52 ambulatory patients (Wilson, Rayos, Yeoh, Gothard, & Bak, 1995). 
The level of perceived exercise intolerance during daily activities was evaluated using 
MLHFQ scores. All groups in the study exhibited similar levels of fatigue and dyspnea at 
comparable workloads and had comparable total scores for the MLHFQ . 
 The effect of exercise on patients with HF QOL has been studied using the 
MLHFQ. A study to compare exercise training on a cycle ergometer (focusing on major 
muscle mass) and aerobic knee-extensor training (focusing on minor muscle mass) was 
conducted in 24 patients with HF who had completed their first exercise training more 
than one year previously (Tyni-Lenne et al., 1999). Subjects were randomized into 
control and exercise groups. Physiological measurements such as citrate synthase 
activity, blood lactate concentration, peak oxygen uptake, and plasma norepinephrine 
concentration were measured. QOL was measured using the MLHFQ. MLHFQ scores 
showed improvement in the health-related quality of life (p <0.05) only after knee-
extensor training. Physical training was beneficial in previously trained patients with HF 
and aerobic training involving minor muscle mass showed greater efficiency than 
training involving major muscle mass. 
 In a study with 22 ambulatory males, the effects of an exercise training program 
on patients with HF (NYHA functional class II-III) attributed to left ventricular systolic 
dysfunction and dilated left ventricle were studied (Tokmakova, Dobreva, & Kostianev, 
1999). Subjects were randomized into control and training groups. The reduction in 
scores from baseline and at eight weeks as measured by the MLHFQ (p < .001) reflect 
the reduction of symptoms and the improvement in health-related QOL. 
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 Using the MLHFQ, QOL was studied with implanted device intereventions (Gras 
et al., 1998). The Medtronic InSync pacemaker left ventricular pacing lead was 
implanted and studied with 68 patients. There was a clinical benefit among surviving 
patients, which was corroborated by a significant improvement in NYHA functional 
class, significant narrowing of the paced QRS complex, a significant decrease in the 
interventricular mechanical delay, a trend toward an increase in the duration of 
ventricular filling, and a longer distance covered during a 6-minute walk test. 
Improvement was noted in all MLHFQ scores.  
Short Form-36v2 Health Survey 
 The SF-36 (Appendix B) was developed by John Ware in 1992 as part of the 
Medical Outcomes Study (MOS) which was supported by the Rand Corporation. It is a 
patient self report survey of general health status that has been used to assess overall 
QOL in a variety of patient populations. It has been used to measure QOL in chronic 
disease conditions such as cancer, arthritis, stroke, diabetes, pain, coronary disease, 
HF, hip and knee replacements, and chronic obstructive pulmonary disease. 
 Initially comprised of 108 questions, which was determined to be too lengthy to 
be effective (Brazier et al., 1992). Using question analysis and further research it was 
reduced to 36 questions and renamed the SF-36. In 1996 the SF-36 (SF-36v2) was 
revised to correct minor deficiencies identified in the original version. Five level 
response choices were added in two role functioning scales, mental health scale, and 
vitality scale. Improvements were also made in instructions to participants (Ware et al., 
2000). 
 With only 36 questions it is estimated to take approximately 5 to 10 minutes to 
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complete (Brazier et al., 1992; Martin, Engelberg, Agel, & Swiontkowski, 1997; Moy et 
al., 1999). It was constructed to measure eight health attributes using eight multi-item 
scales containing two to ten items each. The eight sub-scales measure physical 
functioning, role-physical, bodily pain, general health, vitality, social functioning, role-
emotional, and mental health. MOS researchers developed the questions from a variety 
of instruments already in use: the General Psychological Well-Being Index, the Health 
Perceptions Questionnaire, the Health Insurance Experiment, and the Well-Being 
Profile (Cramer & Spilker, 1998). There is a three, five, or six point rating scale that can 
be used for each of the 36 questions. 
 The SF-36 has had rapid acceptance as a measurement tool for health related 
QOL because of its brevity and favorable psychometric properties (Stadnyk, Calder, & 
Rockwood, 1998). There is a large body of literature to support the reliability and 
construct validity of this tool using both internal consistency and test-retest methods 
(Vickrey, Hays, Genovese, Myers, & Ellison, 1997). This tool has been used in a variety 
of chronic disease populations. 
 Functional outcomes at an average of six months after outpatient rehabilitation 
were investigated in a pilot study with a sample of 42 patients receiving physical therapy 
for low back, neck, and other musculoskeletal problems (J. G. Baker, Fiedler, 
Ottenbacher, Czyrny, & Heinemann, 1998). For predicting improvement verses no 
improvement using the SF-36 sub-scales, the physical functioning sub-scale was 
predictive of change in general health. 
 Chronic obstructive pulmonary disease (COPD) outpatients (n=472) were 
surveyed to evaluate change on both the Chronic Respiratory Disease Questionnaire 
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(CRQ) and the SF-36 (Wyrwich, Tierney, & Wolinsky, 1999). Among SF-36 sub-scales 
demonstrating acceptable reliability and reasonable variance, the percent of individuals 
within each change category was consistent with those seen in the CRQ dimensions. 
The SF-36 and two disease-targeted health related QOL instruments were administered 
to 171 adults with multiple sclerosis (Vickrey et al., 1997). Results indicate that the 
disease-targeted scales provided unique information not captured by the generic 
measure. Additional information was gained by supplementing the SF-36 with selected 
disease specific scales. 
 Patients with severe chronic airway limitation being assessed for home oxygen 
therapy (n=60, 32 males and 28 females) at the Flinders Medical Centre, Adelaide, 
South Australia were administered two generic QOL instruments, the Nottingham Health 
Profile and the SF-36 (Crockett, Cranston, Moss, & Alpers, 1996) . Patients with severe 
chronic airway limitations were experiencing severe impairment in their QOL in 
comparison to age-matched South Australian norms, with physical disability the major 
limitation. There were several significant correlations between the domains of the SF-36 
and the Nottingham Health Profile which were predominantly gender-specific . 
 The SF-36 has been used in measuring QOL in heart related diseases. A 
prospective, repeated-measures design was used to examine functional status in 
patients with a coronary artery bypass graft (CABG) over time (Barnason, Zimmerman, 
Anderson, Mohr-Burt, & Nieveen, 2000). Baseline data was obtained by patient 
interview in the hospital setting after CABG surgery, at three months, at six months, and 
at 12 months after surgery. Baseline scores on seven of the eight sub-scales of the SF-
36 were significantly lower than at three, six, and 12 months after surgery. Role-
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emotional functioning baseline scores were not significantly lower than three month 
scores; however, baseline scores were significantly lower than six and 12 month scores. 
Three month scores were also significantly lower than six or 12 month scores except for 
the scales measuring social and general health functioning. The results of the study 
provide a basis for determining areas of functional limitations during recovery from 
CABG surgery. Study results are also the foundation for evaluating outcomes of 
patients with a CABG when specific interventions (pain management, psychosocial 
support, physical strengthening, fatigue management) are implemented during 
hospitalization, home recovery, and rehabilitation to target optimal psychosocial and 
physiologic functioning of patients post CABG. 
 The relationship between patients with chronic stable angina (n=55) ratings and 
current health status was studied using multiple tools including the SF-36 (Chen, Daley, 
& Thibault, 1996). Correlations between ratings for both health states and scales of the 
SF-36 were positive, with some reaching statistical significance. The study concluded 
that having patients rate current health and symptom free health is a useful measure of 
treatment effectiveness for specific symptoms in clinical trials and patient care. It can 
help patients and clinicians prioritize multiple health problems. 
 In another study, 51 patients with sleep apnea were administered the SF-36 
before treatment for sleep apnea was initiated and at four weeks into treatment (L. S. 
Bennett, Barbour, Langford, Stradling, & Davies, 1999). Compared with general 
population data, the dimensions of energy and vitality and physical role limitation were 
abnormal before treatment (p<0.05) and normalized with treatment. Sleepiness and 
pretreatment SF-36 values correlated significantly. 
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 QOL in sleep apnea patients (n=108) treated with nasal continuous positive 
airway pressure was studied (Jenkinson, Stradling, & Petersen, 1997). The baseline 
SF-36 scores revealed substantial adverse effects on subjective health of patients with 
obstructive sleep apnea. Treatment with nasal continuous positive airway pressure 
improved scores on the SF-36. 
 The health status of bone marrow transplant survivors (n=251) was compared to  
age-adjusted population health-related QOL with the SF-36 (Sutherland et al., 1997). 
On average, survivors had some diminished QOL relative to the health status of the 
population in general. Time post transplant had a significant influence on QOL. Patients 
with less than three years from transplant experienced considerable impairment while 
those who had survived beyond this point were indistinguishable from the normal 
population in most domains and significantly better in certain psychosocial aspects of 
health. The study concluded that 81% of patients were satisfied with the QOL outcome 
that they had achieved and 94% would recommend a bone. 
 In a study of 85 patients with musculoskeletal tumors, the population experienced 
health status and functional deficits in each of the eight SF-36 assessed scales 
(Bruckner, Cluett, & Conrad, 1998). Data showed that the most severe deficits were 
experienced by patients who had diagnoses of bone tumors and malignant tumors. The 
data allows the physician to understand the presenting condition from the patient's 
perspective and is an important and often neglected aspect of the overall assessment of 
the health of the patient on presentation. This study shows that the SF-36 is a practical 
and effective method for documenting perceived deficits in health status in patients with 
musculoskeletal tumors. 
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 The SF-36 has been used in a variety of patient ages including the adult 
population. In a study of 13,042 randomly selected subjects ages 18 to 64 years, the 
SF-36 was administered in a community setting to obtain normative values (Jenkinson, 
Coulter, & Wright, 1993). The survey achieved a response rate of 72% (n = 9332). 
Internal consistency of the different dimensions of the questionnaire was high. 
Normative data broken down by age, sex, and social class were consistent with those 
from previous studies. 
 The SF-36 has been administered in the elderly population (ages 65 and older). 
Elderly patients with osteoarthritis were compared with that of their peers with no 
chronic illnesses to investigate the associations between analgesic use and QOL 
(Briggs, Scott, & Steele, 1999). Osteoarthritis  patients had significantly (p <.05) lower 
scores than control patients in all QOL scales. Osteoarthritis patient scores were lowest 
for the scales of role-physical, bodily pain, and physical functioning. 
 The SF-36 has been used in the HF population. In a study to assess the 
functioning and well-being of older patients presenting with HF, the SF-36 was 
administered before ACE inhibitor treatment was initiated (Jenkinson, Jenkinson, 
Shepperd, Layte, & Petersen, 1997). The conclusion was that ACE inhibitor treatment, 
while lengthening life, has a relatively limited impact on QOL. 
 The QOL of women HF patients (n=691) was compared with women with other 
chronic conditions (Riedinger et al., 2002). Compared with the normative group of 
women, women with HF had significantly lower QOL, especially in the areas of vigor, 
activities of daily living, social activity, and general health. The study concluded that 
women with HF had poorer QOL than do other chronic disease populations. 
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 A QOL study of gender differences among patients (n=435) admitted with HF 
was measured. Health-related QOL was measured by the SF-36 (Chin & Goldman, 
1998). The study concluded that one year mortality in both genders was high and QOL 
was low in patients admitted with HF. Women had less improvement in physical health 
status and perceived their QOL to be lower than male subjects, thus they may require 
different HF interventions. 
 QOL scores for HF patients were measured in a study of 50 patients (Havranek 
et al., 1999). The SF-36 and the MLHFQ were administered. There were significant (p< 
0.05) curvilinear relationships between the physical function scale of the SF-36 and the 
MLHFQ physical sub score. The study concluded that these tools are valid measures of 
QOL in patients with HF, and cost-effectiveness analyses of HF treatments 
incorporating tools in the outcome measure can be meaningful. 
 Another study (Pilote et al., 1995) compared functional status and QOL in 
Americans and Canadians with and without prior symptoms of heart disease. QOL was 
generally better in the 934 Americans than in the 278 Canadians, with overall health 
rated as excellent or very good in 30% of Americans versus 20% of Canadians (p = 
.0001). Similar emotional and social health scores were obtained. The functional status 
of patients without prior symptoms of heart disease is similar in Americans and 
Canadians. However, among patients with previous symptomatic heart disease, 
functional status is higher in Americans than in Canadians. This difference may be due 
to different patterns of medical management of heart disease in the two countries. 
Self Care Resource Inventory 
 The SCRI tool was developed by Baas in 1992 to fill a gap in instrumentation to 
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measure self care from the MRM perspective (Baas, 1992; Baas et al., 1997). The tool 
(Appendix C) is a 35 item, Likert scale (rating from 0 which is none to 4 which indicates 
a great deal), self-reporting instrument that measures biophysical, psychological, 
cognitive, spiritual, and social needs. Using the MRM concepts of internal and external 
self care resources, the sub-scales measure what patient resources are needed by the 
internal and external self care resource inventory needs (SCRIN) and the internal and 
external self care resource inventory availability (SCRIA) (Baas et al., 1997). Each sub-
scale is summed with a possible total 0 to 140 (Baas et al., 1997). At present this tool 
has only been utilized in the cardiac population (in both patients with HF and myocardial 
infarction) and has been used in a limited number of studies. 
 One of the first published studies using the SCRI surveyed patients with HF 
(n=38) regarding various dimensions of QOL. No differences were found in the 
resources needed or available, physical or emotional symptoms, total activity or health 
related QOL among the groups (Baas et al., 1997). Patients post myocardial infarction 
(MI) (n=84) were studied between three and six months post discharge regarding 
activity levels. There was no difference reported in activity level between those who 
participated in cardiac rehabilitation sessions and those who did not (Baas, 2004). 
 D. Modeling Role Modeling Theory 
 The Modeling Role Modeling (MRM) theory has been applied in many research 
studies dealing with the promotion and maintenance of an individual’s health. The 
theory has been used in studies of chronic diseases and their impact on the daily lives 
of individuals. 
 The theory was first used to study hospitalized medical surgical patients (n=46) 
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(H. Erickson & Swain, 1982). Three classes of significantly different adaptive potential 
were identified: the alarm and impoverished states were considered as stress states, 
while the equilibrium state was considered a non-stress state. Although it was possible 
to distinguish stress from nonstress states, using only physiological parameters, 
psychological parameters were required to distinguish between the stress states of 
arousal or impoverishment. The study concluded that nursing interventions based on 
differentiated assessments of individuals adaptive reserve would be more effective than 
nursing interventions that do not take this into account. 
 COPD patients were studied (n=109) to test the MRM theory describing the 
relationships among psychosocial resources (strength of psychosocial attributes and 
basic need satisfaction), perceived stress, disease severity, and symptomatic 
experience (Leidy, 1990). The psychosocial attributes variable was a significant 
predictor of basic need satisfaction for both sexes. For males, basic need satisfaction 
and stress were significant predictors of symptomatic experience, while psychosocial 
attributes were not. For females, the psychosocial attributes variable was a significant 
predictor of symptomatic experience, while basic need satisfaction and stress were not. 
 In a study of diabetic patients (n=94) research was undertaken to assess spiritual 
well-being as an internal coping resource to buffer the effects of uncertainty on 
psychosocial adjustment (Landis, 1996). The findings suggest that spiritual well-being 
may be an important internal resource for persons forced to adjust to uncertainty related 
to long-term health problems such as diabetes mellitus. 
 In the cardiac population the MRM theory has been utilized in HF studies. 
Thirty-eight individuals undergoing different treatment regimens for HF were surveyed 
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regarding various dimensions of QOL (Baas et al., 1997). Results suggested that by 
using the MRM theory to develop nursing interventions it could enhance resources that 
could improve QOL in patients with HF. 
 An exploratory study was conducted with patients with HF (n=138) on the 
physical limitations imposed by a chronic illness (Baas, Beery, Fontana, & Wagoner, 
1999). The participants reported an overall high level of satisfaction with their lives, 
despite the presence of a chronic disease. It was felt that by successfully dealing with 
past developmental challenges (as per the Erikson’s developmental stages), the 
individuals had residual positive energy to overcome their current health problems. The 
MRM theory was supported by the linkages between the mood states, life satisfaction, 
and developmental residual. 
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 III. METHODS 
 This chapter will discuss the study design, setting, sample, instruments, and 
procedures for data collection and analysis. 
 A. Design 
 A descriptive design was used to determine quality of life (QOL) measurements 
when studying patients with heart failure (HF) in two different settings for medical 
management and follow-up. Using the settings as independent variables, QOL scores 
(dependent variables) were compared between HF subjects from the disease specific 
HF clinic and the HF subjects from physician run private practices. 
 B. Setting 
 Two settings were compared, a disease specific HF clinic and private physician 
practices. These settings were studied because they are the primary settings utilized for 
the medical management of the HF population. 
 Disease Specific Heart Failure Clinic 
 The HF clinic is a more recent approach to disease specific care. The HF clinic  
provides patient management utilizing a multidisciplinary approach (nursing, medicine, 
pharmacy, physical therapy, social work, nutrition) with a focus on the specific HF 
diagnosis. One HF clinic setting was studied in this research. The university based clinic 
had services and interventions that are delineated as they pertain to the needs of the 
patient with HF. As a designated clinic space within the university hospital, the clinic has 
a reception/sign-in area, patient/family waiting area, six exam rooms, adjacent areas for 
cardiac diagnostic testing (echocardiogram, cardiac stress testing, electrocardiograms), 
patient education space with written materials, and staff areas (conference room, 
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medical record area, office areas). Other medical clinics (pacemaker, anticoagulant, 
cardiac device, general cardiology) utilize the same areas, but are scheduled on 
different weekdays and times. Family/significant other involvement was encouraged 
through attendance at office visits and participation in educational opportunities. 
 Staff permanently assigned to the HF clinic include physicians, cardiologists, 
medical residents, cardiology fellows, registered nurses (RN’s), secretarial support, and 
cardiac technicians. Adjunct staff can be utilized from hospital resources which include 
pharmacists, dieticians, other physician specialists, social workers, physical therapists, 
and cardiac rehabilitation staff. Staff did not include advanced practice nurses. 
Designated cardiologists scheduled time slots throughout the week in which HF patient 
appointments are specifically scheduled. Patients with HF are routinely followed by a 
primary physician. Staff members (physicians, RN’s) are on call 24 hours a day to 
answer patient questions in order to provide early intervention, direction, and 
information. Patients and families/significant others are provided with phone numbers so 
they can access staff members at any time. 
 HF interventions available through the clinic include (a) pharmacologic therapy 
adjustment (experimental and non-experimental medications) that can be administered 
orally or intravenously, (b) behavior modification (smoking cessation, weight reduction, 
sleep enhancement, Dean Ornish program), (c) dietary intervention (weight reduction, 
sodium restriction, fluid management), (d) patient education (written materials, 
audiovisual teaching adjuncts, verbal discussion), (e) device therapies for dysrhythmia 
control (atrial ventricular synchronous pacemakers, biventricular pacemakers, automatic 
internal defibrillators), (f) cardiac devices (ventricular assist devices),  
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(g) surgical intervention (coronary artery bypass graft, valve replacement, ventricular 
mesh), (h) screening for cardiac transplant candidates, and (i) post cardiac transplant 
follow-up. All patient evaluation, screening, education, and interventions (with the 
exception of cardiac transplant) ordered in the HF clinic are provided through the 
services of the hospital. 
 Physician Private Practice 
 The private physician practice has been the mainstay for providing medical care 
to patients with chronic diseases. The private physician practices in this study involve 
two private physician offices that provided care to patients with a HF diagnosis. Both 
physicians are board certified cardiologists with intervention privileges in area hospitals. 
Located in a non-university setting, the physician practices also provided medical care 
for a wide range of patients with medical conditions. 
 The private physician practices are free standing physician offices. The offices 
have a reception/sign-in area, patient/family waiting area, from three to six exam rooms, 
cardiac diagnostic testing area (for electrocardiograms, cardiac stress testing, 
echocardiogram), and staff areas (medical record area, conference room, office space). 
Office staff included the physician, registered nurse, physician assistant, family nurse 
practitioner, and secretarial support. 
 HF interventions available at the office included (a) pharmacological therapies 
and adjustment (administered orally), (b) behavior modification, (c) patient education 
(written materials for patients/families regarding diet, smoking cessation, weight 
control), (d) screening for device implantation, (e) follow up checks for implanted 
devices, (f) cardiac surgery evaluation, and (g) other types of cardiovascular consults. 
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Referral to outside resources is possible and can be scheduled as additional 
appointments. The outside resources included cardiac rehabilitation, Dean Ornish 
program, smoking cessation, and weight reduction. 
 Summary 
 While there are many similarities between the two settings (staffing, cardiac 
testing accessibility, access to cardiologists, and patient education materials), there are 
several differences between the two study settings. The physician office has a family 
nurse practitioner on staff while the HF clinic is staffed with entry level registered 
nurses. Access to interventions varied between the two settings. The HF clinic has 
access to ventricular assist devices, ventricular mesh, transplant screening, and 
experimental drugs. The physician office can refer to an outside cardiologist for these 
interventions, which necessitates an additional appointment and travel. 
 Another difference is the diagnosis specific patient population. At the HF clinic, all 
patients have a diagnosis of HF and appointments are grouped on specific days. In the 
physician office all types of medical and cardiac diagnoses, including HF, can be 
scheduled on all office days which necessitates a patient to patient shift in practice 
standards and critical thinking. 
 Access to 24 hour health care personnel is different between the two treatment 
locations. At the HF clinic, 24 hour access for questions and concerns is available by 
both physicians and nurses. At the physician office 24 hour access is available for 
physician services only. 
 C. Sample 
 Convenience samples from the HF Clinic and private physician practice were 
  
55
used. Inclusion criteria included: 
1. Adult males and females ages 18 or older 
2. Diagnosis of HF for greater than 6 months 
3. Current enrollment in HF medical management (either a disease specific HF 
clinic or private physician practice) 
4. Ability to read and write English in order to complete the questionnaire 
5. Successful verbal validation of orientation to time, place, person 
 D. Instruments 
 The instruments used for data collection consisted of the Minnesota Living with 
Heart Failure Questionnaire (MLHFQ) to identify disease specific QOL, the Short Form 
36v2 Health Survey (SF-36v2) to identify health related QOL, and the Baas Self Care 
Resource Inventory (SCRI) to identify the effect of self care resources on QOL. Each 
tool will be discussed from the standpoint of statistical assessment, patient populations, 
and reliability and validity. 
 Minnesota Living with Heart Failure Questionnaire 
 The MLHFQ is the most validated questionnaire for measuring QOL in the HF 
population at present (Cohen-Solal et al., 1994; Green et al., 2000; Guyatt, 1993). The 
21 questions were identified from a comprehensive list of sickness-related dysfunctions 
from the Sickness Index Profile, a health related QOL tool (Rector, Kubo et al., 1987). 
The questions can be grouped into two categories with two sub-scores: physical 
dimension and emotional dimension. The physical dimension sub score is calculated 
with eight questions (question number 2, 3, 4, 5, 6, 7, 12, and 13). Questions 
contributing to this sub-score take into account activities such as walking, climbing 
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stairs, doing errands, working around the house, and engaging in recreational activities. 
The emotional dimension or psychological sub-score is calculated with five questions 
(question number 17, 18, 19, 20, and 21) and addresses sleeping problems, fatigue, 
and overall well-being. The psychological and emotional dimension sub-scores were 
identified by factor analysis and can be examined to further characterize the effect of HF 
on a patient’s life (Rector & Cohn, 1992). The MLHFQ has been translated into other 
languages and the resulting QOL scores tested for reliability and validity (Briancon et 
al., 1997). 
 The questionnaire was tested for internal consistency using a Cronbach Alpha 
statistic. In 1987 subjects with left ventricular dysfunction (n= 83) were surveyed using 
the MLHFQ (r= .80). The results suggested that this tool is a valid representation of 
patient impairment (Rector, Kubo et al., 1987). A weighted Kappa statistic of 0.84 was 
cited in this study for the two baseline self-assessments. Internal consistency was also 
evaluated using the Spearman Rank Order correlation coefficients between each item 
and the overall score. Item scores ranged from 0.35 to 0.86 (Rector, Kubo et al., 1987). 
A study of HF patients in a randomized, double-blind, placebo-controlled 3-month trial of 
pimobendan (n=198) was used to measure the reliability and validity of the MLHFQ (r= 
0.93) (Rector & Cohn, 1992). 
 The MLHFQ was compared to the New York Heart Association (NYHA) 
Functional Classification System for HF (Dracup et al., 1992). This functional 
classification system has long been used to measure the physical ability of a patient to 
engage in daily activities in relation to the degree of symptoms. In the development of 
the MLHFQ, a comparison with the NYHA classification was done with 83 patients and 
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a correlation of .80, p<.01 was obtained. It has a correlation statistic of .80 with a global 
rating of .60 (Guyatt, 1993). 
 The MLHFQ was specifically designed for use in patients with HF and has been 
used extensively with this population over the past 10 years. As a disease specific tool 
that measures QOL for the HF population, it has been shown to be valid, reliable, and 
effective (al-Kaade & Hauptman, 2001; Green et al., 2000; Guyatt, 1993; Sheth et al., 
2002; Shively et al., 1996). Permission was obtained from the University of Minnesota 
(Appendix D) to administer the tool to measure the perception of disease specific QOL 
in patients with HF for this research. 
 Short Form-36v2 Health Survey 
 The SF-36 Health Survey (SF-36) and SF-36v2 Health Survey are comprised of 
36 items with 8 sub-scales: physical functioning, role-physical, bodily pain, general 
health, vitality, social functioning, role-emotional, and mental health and consists of two 
major summary scales, physical and mental. The Medical Outcomes Trust provides 
standard instructions and/or computer programs for scoring the questionnaire (Ware et 
al., 2000). The scoring program “SF Health Outcomes Scoring Software - Basic Module” 
was used to calculate the sub-scores for this research (Saris-Baglama et al., 2004). 
 The tool can be self-administered, administered by computer, or administered by 
an interviewer in person or by telephone. For this research the tool was administered by 
an interviewer. Permission from QualityMetrics Incorporated (Appendix E) was obtained 
to administer the tool to measure health related QOL in patients with HF. 
 The SF-36v2 gained rapid acceptance as a measurement tool for health related 
QOL because of its brevity and favorable psychometric properties (Stadnyk et al., 
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1998). There is a large body of literature to support the reliability and construct validity 
of this tool using both internal consistency and test-retest methods (Vickrey et al., 
1997). In a general population study (n=11,186) the tool had a correlation value of .68 
(Stewart, Hays, & Ware, 1988). In 1993, a study of 9,332 working age adults showed an 
internal consistency with the 8 sub-scales as ranging from .76 (social functioning scale) 
to .90 (physical functioning) (Jenkinson et al., 1993). Internal consistency was rated as 
good. Baas et al (1997) studied chronic HF patients (n=38) using the SF-36 and 
measured the alpha coefficient as >.80 (with a range from .75 to .91), and stability as 
r=.79 with the eight sub-scales (Baas et al., 1997). Patients with HF were studied In the 
Studies of Left Ventricular Dysfunction (SOLVD) trial (n=308) and the study reported 
high values of internal consistency with a Chronbach’s alpha of >.80 (Berry & 
McMurray, 1999). 
 Content validity has also been addressed. Symptoms and issues that address a 
specific condition are not included because the SF-36v2 is a generic measure. Studies 
to date addressed content and concurrent criterion, and construct and predictive 
validity. It is primarily designed for persons age 14 and older (S. J. Bennett et al., 1999; 
Chrispin, Scotton, Rogers, Lloyd, & Ridley, 1997; Mosconi, Cifani, Crispino, Fossati, & 
Apolone, 2000). Although it was developed in the United States, it has been translated 
into other languages (for example French, German, Swedish, and Dutch). 
Self Care Resource Inventory 
 The Self Care Resource Inventory (SCRI) tool was developed by Baas in 1992 to 
fill a gap in instrumentation to measure self care from the Modeling Role Modeling 
(MRM) theory perspective. Internal consistency was assessed using Chronbach’s alpha 
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with results ranging from .79 to .91 in a study of 38 patients with HF (Baas et al., 1997). 
In a study of 84 post myocardial infarction subjects the SCRI was administered with a 
Chronbach alpha of .93 for the SCRIN and SCRIA scales (Baas, 2004). As a newer 
instrument, published information on this tool is limited. 
 The SCRI is utilized in this dissertation research to measure self care resources, 
(both internal and external) in patients with HF based on the Modeling Role Modeling 
(MRM) theory which is the conceptual framework for this study. Internal self care 
resources can be described as those factors which make the individual unique. This tool  
measures such factors as hope, control, self-efficacy, future orientation, and knowledge 
of the illness. External self care resources are those social factors which are separate 
from the individual. Measurement of such factors as social support, social network 
financial assistance, health care provider support, and help with driving/shopping were 
measured by the tool (Baas et al., 2001). 
 The Self Care Resource Inventory Needs (SCRIN) sub-scale score is the sum  
measure of the amount of resources the individual perceives to be needed for recovery. 
The internal needs sub-score is calculated with 12 questions (question numbers 3, 6, 7, 
8, 9, 13, 15, 24, 26 29, 30, and 31) and the external needs sub-score with seven 
questions (question numbers 4, 11, 16, 18, 21, 32, and 35). The Self Care Resource 
Inventory Availability (SCRIA) sub-scale score is the sum measure of the perceived 
amount of resources that the individual has accessible to help cope with the stressors 
during recovery (Baas, 1992). The internal availability sub-score is calculated with 13 
questions (question numbers 3, 6, 7, 8, 10, 12, 17, 19, 21, 23, 26, 29, and 30) and the 
external availability sub-score is calculated with 11 questions (question numbers 4, 5, 
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11, 15, 16, 18, 20, 32, 34, and 35). Permission from Dr. Linda Baas (Appendix F) was 
obtained to administer this tool to measure self care resources. 
 Patient Demographic Questionnaire 
 A list of demographic questions about medical history focusing on HF diagnosis 
and treatment was completed by the participants (Appendix G). Subject information did 
not include any specific patient identifiers (name, address, medical record number, 
social security number). Content validity for the demographic questionnaire was 
obtained through completion of a pilot study of the study questionnaires. 
 A pilot study was conducted to review the questionnaire presentation, to review 
the demographic questions, and to obtain time requirements for the study participants. 
A convenience sample of 14 subjects was obtained to review the questionnaires. 
Subjects were approached from each decade of life from age 40 to 70. Instructions 
requesting written input was included in a letter to the participants (Appendix H). The 
ages of participants in the pilot study ranged from 48 to 79 with a mean age of 60.2. 
There were at least three subjects from each decade of life. 
 The participants were asked to record their start and finish time in completing the 
questionnaires. The time needed to complete the questionnaires ranged from 18 
minutes to 67 minutes with a mean of 37 minutes. Questions about the format of the 
questionnaires were asked. The participants were asked if they were able to read the 
size of print (font) without problems. The size of print (12 point) was deemed adequate 
by 14 (93%) of the 15 participants. No changes in the overall print size were made. 
 One of the pilot study questions involved the shading of every other question to 
improve readability. The alternate questions on the MLHFQ and SCRI were shaded in 
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the pilot study while the SF-36v2 questions were not. The alternate question shading 
was deemed helpful by 10 (71%) of the 14 participants. The SF-36v2 questionnaire was 
subsequently revised to include the shading of alternate questions. The pilot study 
questionnaires were printed on white paper and 14 (100%) of the respondents deemed 
this adequate. The participants were asked if having the questionnaires printed front 
and back made it harder to complete the questions. Eleven or 79% responded that it did 
not make completing the questionnaires more difficult. The questionnaires in the 
research study were printed front and back. 
 The content of the demographic questionnaire was evaluated by the participants. 
It was suggested that for clarification the questions should be numbered. If the 
respondent had a concern about a question, the number would make the question 
easier to identify. Question numbers were added to the patient demographic 
questionnaire. Several comments were noted regarding the medical condition listing 
(question number 10). Some of the diseases listed were abbreviated and some had an 
explanation while others did not. The disease list was edited and made consistent with 
both the abbreviation and explanation. Input was received regarding the list of 
treatments the patient was currently receiving (question number 18). A question 
regarding which HF treatments or category of drugs were part of the treatment regime 
was found to be confusing for respondents. Respondents placed multiple question 
marks in drug category options and questions arose regarding the disease 
abbreviations. The drug category question was deleted and a decision was made that 
the researcher would evaluate the treatment and medication list and determine the 
categories prescribed for the subjects. 
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 Comments were requested pertaining to the presentation of the questionnaires. 
Five of the respondents provided input on the format of the pages which was 
incorporated into the final questionnaire draft. The pilot study participants felt the 
questions were very clearly stated on the MLHFQ. They also commented that having 
the 0 to 5 scale with definitions listed was beneficial. The font size of the SCRI 
instructions (10 point ) was reported to be too small. The font was enlarged to a 12 point 
font to make the size consistent on all four of the questionnaires. The SF-36v2 
questionnaire also received several format comments. Three of the participants 
suggested that the major questions should be bolded for ease of reading. All of the 
above suggestions were incorporated into the revised questionnaire packet. 
 Medical Chart Questionnaire 
 Medical information was obtained from study participants and validated by the 
researcher through review of the subject’s medical record (Appendix I). This included 
medication history, medical history, and number of office/clinic visits. Additional 
information obtained from the medical record included ejection fraction, type of HF 
(systolic, diastolic, combined), echocardiogram results, cardiac catherization results, 
NYHA classification, presence of left bundle branch block, date first seen in office/clinic, 
failed treatments, insurance agency, and pacemaker information. Validation of patient 
information on the demographic questionnaire was obtained for the patient medical 
history, medication history, and number of physician/clinic visits or calls. 
 E. Sample Size 
 Sample size for this research study was determined by review of previous 
studies using the questionnaires, review of the literature, and calculation using a power 
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analysis formula. Review of the literature showed a wide variety of sample sizes in 
studies using the MLHFQ from 15 (Rector et al., 1996) to 322 (Massie et al., 1993). 
Studies utilizing the SF-36v2 included sample sizes ranging from 61 (Jenkinson, 
Stradling et al., 1997) to 216 subjects (Riedinger et al., 2002). With such a wide variety 
of samples sizes in the literature, a power analysis was conducted. 
 Sample size was calculated using two different methods. A sample-size 
estimation formula for testing for the mean of a normal distribution (two sided 
alternative) formula (Rosner, 1995) was calculated using prior HF studies (Appendix J). 
Using an alpha of .05 with a power of .80, initially a sample size estimation of 150 with 
75 subjects from the HF clinic and 75 subjects from the private physician offices was 
calculated. A second method was conducted using an on-line computer calculator from 
DSS Research (Researcher's Toolkit, 2005) to calculate sample size. Using an alpha of 
.05 and a beta of .50, a sample size of 56 (28 in each group) was obtained. It was 
determined to use a total sample size of 60 (30 in each group) for this research. 
 Using the inclusion criteria, a convenience sample was obtained. The patient 
information brochure (Appendix K) was placed in the HF clinic and physician offices 
prior to the beginning of data collection to inform patients of the study. Each patient 
received a copy of the patient brochure at the time of data collection. 
 F. Protection of Rights of Human Subjects 
  Prior to data collection, approval was obtained from the Duquesne University 
Institutional Review Board (IRB) Committee (Appendix L). On-line education regarding 
the protection of human subjects was completed (Appendix M). Additional approval was 
obtained from West Penn Allegheny Health System Institutional Review Board 
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Committee for the HF clinic site data collection (Appendix N). Additional mandatory 
education regarding the protection of human subjects was required and completed for 
IRB approval (Appendix O). The data collection sites for the private physician offices felt 
the research had been adequately reviewed by the two IRB offices and did not require 
additional approval. 
 To maintain confidentiality, each subject was identified by a study identification 
number. The results of the study were reported as group information only, and no 
subjects were identified. The data is kept in a locked file at the researcher’s home. The 
data (including consent forms) will be maintained in a locked file by the researcher until 
the study and dissemination of the findings is complete. 
 The subjects reported no discomfort or risks associated with this research. The 
only inconvenience was the 30 to 40 minutes of time required to complete the 
questionnaires. There was no cost to the subjects participating in this research. 
 There was no direct benefit to the subjects for participating in this research. One 
indirect benefit was the gathering of quality of life information that could help medical 
professionals improve HF care in the future. 
 G. Procedure for Obtaining Data 
 1. A flyer (Appendix K) was distributed to the HF clinics and private physician 
offices prior to the data collection phase to provide study overview information to 
patients about the research study. The flyer was left in waiting areas as preliminary 
information for patients in the event they would like to participate.  
 2. Patients were informed in writing that data collection would take place 
immediately prior to or after their scheduled visit or they could set up a specific time for 
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data collection. A phone number of the researcher was provided for any questions or to 
arrange a meeting for scheduled data collection. 
 3. Potential subjects who met the inclusion criteria were identified from the 
appointment schedule. To facilitate the identification of patients already enrolled in the 
study, a list of enrolled patients at the data collection site was maintained. This assisted 
the clinic/office staff in easily identifying those patients who were potential study 
subjects and to identify those patients who had already enrolled and completed the 
study. The list was shredded on the last day of data collection. 
 4. Patients were screened for orientation to time, place, and person by the office 
staff. This was done through verbal questions to the subject during their clinic/office 
visit. They were asked their name, where the interview is taking place, the date (day, 
month, year), and name of the current president. 
 5. If orientation was not verified, no further questions were asked and the subject 
was thanked for their participation. No subjects were excluded from participating in the 
study due to orientation. 
 6. If the questions were answered correctly the staff of the clinic/office then asked 
if they would like to talk to the researcher about the study. If they chose not to 
participate, nothing more was done. If they had additional questions about the study, the 
questions were answered by the researcher. 
 7. If they chose to participate in the study, the participants were escorted to a 
designated data collection area (private conference room in physician offices, room 
adjacent to the waiting area at the HF clinic). 
 8. The informed consent form (Appendix P) was then reviewed with the 
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prospective subject. The consent was read by or read to each prospective subject. 
There was one subject who declined to participate in the study at this point because 
review of the medical record was included in the consent. This subject was not included 
in data collection. All subjects were given an opportunity to ask questions and have their 
questions answered. All other subjects who were identified agreed to participate. 
Several subjects (n=10) could not complete the questionnaire at their appointment time 
due to other commitments, but indicated they would like to participate in the study. A 
date and time was agreed upon for the researcher to contact the subject by phone at a 
later time. The researcher made the follow-up phone call and the questionnaires were 
completed via phone interview. 
 9. The researcher asked if there were additional questions the subject had about 
the research process and questions were answered. 
 10. The subject signed three copies of the consent. One copy of the consent was 
given to the subject. The second copy was kept by the researcher. The third copy was 
placed in the patient’s medical record. The consent procedure was completed prior to 
the collection of any data. The copy on the medical record was also used to keep track 
of patients who had previously participated in the study. 
 11. Once informed consent was obtained, the subject was assigned a study 
identification number which would identify the subject and all collected data. 
 12. The researcher verbally reviewed the instructions for completing the 
questionnaires (the patient demographic questionnaire, MLHHQ, SF-36v2, and SCRI) 
and answered any questions that arose at that time. For the first subject, the 
questionnaires were read by the subject and results recorded by the participant. The 
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first subject had multiple questions about the instructions and questionnaires and all 
questions were answered by the researcher. All subsequent questionnaires were read 
to the subjects in interview style and responses recorded by the researcher. This 
allowed the researcher to develop one on one interaction with the subjects which made 
the process more friendly and conversational. The researcher conducted all 60 
questionnaire completion sessions, therefore the data collection environment was 
consistent throughout. 
 13. The researcher answered any questions that arose during the interview 
process. 
 14. When the questionnaires were completed they were reviewed for 
completeness and any blank questions completed. 
 15. The subject was asked if they would like a summary of the study results. If 
the subject answered yes (n=46), an index card was completed with their name and 
home address. There was no reference to the subjects study identification number on 
the postcard in order to maintain confidentiality. The summary will be mailed out at the 
completion of the study and will include a summary of the study findings and a thank 
you to the subjects for participation. 
 16. The researcher reviewed the subject’s medical record and completed the 
chart review data collection tool based on medical chart information and was completed 
following the questionnaire interviews. Additional information regarding the subject’s 
medical condition was gathered which included: ejection fraction, cardiac catherization 
results, echocardiogram results, NYHA classification, type of HF, number of visits to 
clinic/office in past 12 months, failed treatments, and referral history. Information 
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gathered from the subject was validated using the medical record (number of visits, 
number of phone calls, medication history, past medical history). 
 H. Data Analysis 
 Quantitative analysis of the data obtained was conducted. Quantitative analysis 
included the use of independent sample t tests to compare the questionnaire QOL 
scores, SCRI score, and all sub-scores. Descriptive analysis was conducted with the 
patient demographic questionnaire information. The computer program SPSS version 
13.0 was used to record and analyze the research data. 
 Using the Patient Demographic Questionnaire, results were compared between 
two groups (a disease specific HF clinic and physician run private practices) and the 
total sample using mean, range, standard deviation, and independent sample t-test 
statistics. Health related demographic information was compared in the same manner 
using frequency, percentage, and Pearson Chi-Square statistics. 
 Research Questions 
 Research question 1: Does health related QOL differ among patients with HF 
who are receiving medical outpatient care in two different clinical settings: a multi-
disciplinary (nursing, medicine, pharmacy, physical therapy, social work, nutrition) 
disease specific HF clinic and physician run private practices as measured by the 
Medical Outcomes Study SF-36v2. The SF-36v2 was scored using the Quality Metric 
scoring software “SF Health Outcomes Scoring Software - Basic Module” (Saris-
Baglama, 2004) to calculate the 8 sub-scales and the Physical Component Summary 
Scale (PCS) and the Mental Component Summary Scale (MCS). The PCS and MCS 
and the 8 sub-scales were compared using an independent 2 sample t-tests to 
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determine p values. 
 Research question 2: Does disease specific QOL differ among patients with HF 
who are receiving medical outpatient care in two different clinical settings: a multi-
disciplinary (nursing, medicine, pharmacy, physical therapy, social work, nutrition) 
disease specific HF clinic and physician run private practices as measured by the 
Minnesota Living with Heart Failure Questionnaire (MLHFQ). The total score of the 
questionnaires, physical sub-score, and emotional sub-score was compared between 
the groups. The MLHFQ sub-scores were obtained using the scoring guidelines and 
SPSS software. 
 Research question 3: Are there differences in self care resources of patients with 
HF who are receiving medical outpatient care in two different clinical settings: a multi-
disciplinary (nursing, medicine, pharmacy, physical therapy, social work, nutrition) 
disease specific HF clinic and physician run private practices as measured by the SCRI 
for the sub-scales of the SCRIN (internal and external ) and SCRIA (internal and 
external). The two settings were compared using independent t tests for p values. SCRI 
sub-scales scores were obtained using SPSS syntax calculations developed by Dr. 
Linda Baas. 
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 IV. Results 
 This chapter will report all demographic results of the study. It will also present 
the results from the three research questions. 
 A. Demographics 
 Results of the Patient Demographic Questionnaire are presented in Tables 2, 3, 
4, and 5. Results were compared between two groups (a multi-disciplinary disease 
specific HF clinic and two physician run private practices) using mean, range, standard 
deviation, and independent t-test or Chi-Square. A summary of all study subjects is 
included. 
 General demographic information is compared in the same manner in Tables 2 
and 3. Subject age in the total sample ranged from 24 to 85 years of age with a mean of 
64.7. The mean age of the subjects in the HF clinic group was lower (p<.001), at 56.3 
(range 24-79), than the physician practice group at 73 (range 41-85). In the total sample 
41 (68.3%) of subjects were male and 19 (31.7%) were female. There was not a 
significant gender difference (p = .405) between the two groups. The HF clinic subjects 
were 73.3% male (n = 22) and 26.7% female (n = 8) and the physician practice subjects 
were 63.3% male (n = 19) and 36.7% (n = 11) female. 
 Race/ethnicity was surveyed. In the total sample the majority of subjects were 
Caucasian.  Fifty-three subjects (68.3%) were Caucasian and seven (11.7%) were 
African American. There was a significant difference between the two groups (p= .044). 
The HF clinic group had a greater number of African American subjects at 6 (20%) than 
the physician practice group at 1 (3%).  
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Table 2: Health Related Information of Heart Failure Subjects 
 Multi-Disciplinary 
Disease Management 
HF Clinic 
n=30 
Physician Run Private 
Practices 
n=30 
Total Subjects 
n=60 
  
 Mean Range SD1 Mean Range SD Mean Range SD t-test p 
Age 
(years) 
56.3 24-79 15.3 73 41-85 9.5 64.7 24-85 15.2 5.1    <.001 
Length of 
Heart 
Failure 
Diagnosis 
7.9 1-39 8.0 10.9 1-40 9.8 9.4 1-40 8.9 1.3 .197 
# Hospital 
visits in 
past 12 
months 
2.0 0-16 3.3 0.4 0-3 0.7 1.2 0-16 2.5 -2.5 .017 
# ED1 visits 
12 months 
2.4 0-40 7.4 0.3 0-2 0.5 1.4 0-40 5.3 -1.6 .125 
# 
Physician 
Calls within 
12 months 
2.8 0-40 8.0 0.5 0-6 1.3 1.7 0-40 5.8 -1.5 .136 
Physician/ 
Clinic visits 
12 months 
5.5 1-25 4.7 3.0 1-6  1.4 4.3 1-25 3.6  -2.9 .005 
Total # of 
Physicians 
seen 
3.5 1-6 1.2 3.5 2-6 1.2 3.5 1-6 1.2 -0.1 .915 
Miles to 
clinic/ 
physician 
visit 
37.9 2-150 36.3 20.1 1-72 16.7 29.0 1-150 29.4 -2.4 .018 
Initial 
Ejection 
Fraction 
(%) 
27.2 9-60 15.1 44.5 20-80 15.3 35.9 9-80 17.4 4.4 < .001 
Current 
Ejection 
Fraction 
(%) 
23.6 7-50 10.4 41.7 25-80 13.9 32.6 7-80 15.2 5.7 < .001
 
1ED - Emergency Department 
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Table 3: General Demographic Information of Subjects with Heart Failure Subjects 
Characteristic Multi-Disciplinary 
Disease 
Management HF 
Clinic 
n=30 
Physician Run 
Private 
Practices 
n=30 
Total 
Subjects 
n=60 
  
 Number (%) Number (%) Number (%) Chi-
Square 
p 
Gender    0.698 .405 
Male 22 (73.3) 19 (63.3) 41 (68.3)   
Female 8 (26.7) 11 (36.7) 19 (31.7)   
Education    15.33 .032 
< 8 years high school 0 1 (3.3) 1(1.7)   
< 12 years high school 3 (10) 10 (33.3) 13 (21.7)   
Graduated high school 13 (43.3) 10 (33.3) 23 (38.3)   
Vocational School 5 (16.7) 3 (10) 8 (13.3)   
Graduated 2 years College 4 (13.3) 2 (6.7) 6 (10)   
Graduated 4 years College 5 (13.7) 0 5 (8.3)   
Graduate School 0 2 (6.7) 2 (3.3)   
Post-graduate studies 0 2 (6.7) 2 (3.3)   
Race/Ethnicity    4.04 .044 
African American 6 (20) 1 (3.3) 7 (11.7)   
Caucasian 24 (80) 29 (96.7) 53 (88.3)   
Marital Status    12.63 .013 
Single 8 (26.7) 2 (6.7) 10 (16.7)   
Married 19 (63.3) 18 (60) 37 (61.7)   
Widow/Widower 0  8 (26.6) 8 (13.3)   
Divorced 2 (6.7) 2 (6.7) 4 (6.7)   
Separated 1 (3.3) 0 1 (1.7)   
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There were no Asian or Hispanic subjects in the sample. 
 Marital status of the subjects was surveyed. In the total sample the majority or 37 
subjects (61.7%) were married and 10 (16.7%) were single. There was a significant 
difference between the two groups (p =.013). The HF clinic group had eight (27%) 
single subjects and 19 (63%) married subjects. The physician practice group had two 
(6.7%) single subjects and 18 (60%) married subjects. Eight subjects in the physician 
practice group were widow/widowers (13.3%). Four subjects in the total sample were 
divorced (6.7%) with two in each of the two groups. Seventeen percent of both groups 
(five subjects each) reported having zero children. The HF clinic subjects had a range of 
one to four children and the physician practice subjects had a range of one to six. There 
was no significant difference between the two groups related to the number of children 
(p = .317). 
 Years of education were varied in the sample and there was a significant 
difference between the two groups (p = .032). Twenty-three (38.3%) of the total sample 
subjects completed their high school education while 13 (21.7%) completed less than 
12 years of schooling. Twenty-three of the subjects completed some type of education 
post high school. Twenty-seven (90%) subjects in the HF clinic group completed high 
school or post high school education in contrast to 19 (63%) in the physician practice 
group. 
 The overall number of miles subjects in the total sample traveled to the 
clinic/physician appointment ranged from one to 150 miles with a mean of 28.9 miles. 
There was a significant difference in mileage between the two groups (p = .018). The 
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HF clinic subjects traveled a mean of 37.9 miles with a range of two to 150 miles. The 
physician practice subjects traveled a mean of 20.1 miles with a range of one to 72 
miles. 
 All subjects in the total sample had a diagnosis of HF for a mean of 9.4 years 
with a range of one to 40 years. The HF clinic subjects had a HF diagnosis for a mean 
of eight years and the physician practice subjects for a mean of 10.9 years. There was 
no significant difference (p = .197) between the two groups.  
 Initial ejection fraction for the total subjects was 35.9% with range of 9 to 80%. 
Normal ejection fraction (EF) is 50 - 70% (Burkhoff & Weisfeldt, 2000). There was a 
highly significant difference (p=<.001) between the two groups. The HF clinic group had 
an initial EF mean of 27.2% and the physician office group had an initial EF of 44.5%. 
The most current EF mean for all subjects was 32.6% with a range of 7 - 80%. The HF 
clinic group had a current EF mean of 23.6% (range of 7 - 50%) and the physician 
practice subjects had a mean of 41.7% (range of 25-80%). There was a highly 
significant difference (p=<.001) between the two groups. 
 Patients with HF are on a number of medications to improve their health status. 
In this study subjects were asked to list their medication regime and this was compared 
to the medication list in the medical record. The HF clinic subjects had a medication list 
range of three to 14 drugs while the physician practice subjects had a range of four to 
18 drugs. The mean number of medications recorded by patients in the total sample 
compared to those in the medical record differed by less than one medication. The 
range of differences in the number of medications included on both lists ranged from 
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zero to six medications. 
 The number of hospital visits related to problems associated with HF in the past 
12 months had an overall mean of 1.2 with the physician office subjects at 0.4 visits and 
the HF clinic subjects at two. There was a significant difference between the two groups 
(p = .017). The number of physician/clinic visits within the past 12 months had a mean 
of 4.3 with the physician office group at three and the HF clinic group at 5.5. There was 
a significant difference between the two groups (p = .005). 
 In Table 4 the standard medicine regime of HF subjects is shown. The frequency 
of failed medications are included. Failed medications are defined as those medicines 
that patients have been prescribed, but have been discontinued due to side effects, 
adverse reactions, or intolerance.  
 Beta blockers were prescribed in 83.3% of total subjects and there was not a 
significant difference between the two groups (p = .757). The HF clinic group had beta 
blockers prescribed in 86.7% of subjects and in the physician office group in 80% of 
subjects. 
Diuretics were prescribed in 78.3% of the total subjects (80% in the physician 
practice group and 76.7% in the HF clinic group). There was not a significant difference 
between the two groups (p= .921). Potassium sparing diuretics were prescribed in 
31.7% of all subjects. In the physician office group 10% were prescribed these diuretics 
and 53.3% in the HF clinic group. There was a significant difference between the two 
groups (p=<.001). Eleven percent of all subjects failed on this therapy. 
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Table 4: Utilization of Standard Heart Failure Medications  
 Multi-Disciplinary 
Disease 
Management HF 
Clinic 
n=30 
Physician Run Private 
Practices 
n=30 
Total Subjects 
n=60 
Medication Yes (%) Failed (%) Yes (%) Failed (%) Yes (%) Failed (%) Chi-square p 
Beta 
Blocker 
26 (86.7) 1 (3.3) 24 (80) 2 (6.7) 50 (83.3) 3 (5) .056 .757 
Diuretic 23 (76.7) 4 (13.3) 24 (80) 3 (10) 47 (78.3) 7 (11.7) .164 .921 
Potassium 
Sparing 
Diuretic 
16 (53.3) 4 (13.3) 3 (10) 2 (6.7) 19 (31.7) 6 (10) 15.9 <.001 
Aspirin 16 (53.3) 0 24 (80) 1 (3.3) 40 (66.7) 1 (1.7) 6.86 .032 
Angiotensin 
Receptor 
Blockers 
(ARB) 
21(70) 5 (16.7) 10 (33.3) 2 (6.7) 31 (51.7) 7 (11.7) 14.1 .001 
Angiotensin 
Converting 
Enzyme 
Inhibitor 
(ACEI) 
3 (10) 7 (23.3) 12 (40) 6 (20) 15 (25) 13 (21.7) 7.48 .024 
  
 Aspirin was prescribed 66.7% of the time in subjects in the total sample with 10% 
failing on the therapy. Aspirin was prescribed in 80% of the subjects in the physician 
office group and 53.3% in the HF clinic group. There was a significant difference 
between the two groups (p = 0.32). 
 The initiation of angiotensin receptor blockers (ARB) occurred in 51.7% of HF 
subjects. There was a significant difference (p = .001) between the two groups. The HF 
clinic group was prescribed ARB’s 76.7% of the time while the physician practice group  
prescription rate was 33.3%. Approximately 12% of subjects failed on this therapy. 
Angiotensin converting enzyme (ACE) inhibitors were prescribed in 25% of all study 
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subjects. In the HF clinic group three (10%) subjects were currently prescribed an ARB 
and in the physician practice group 12 (40%) were currently receiving an ARB. There is 
a significant difference (p=.024) between the two groups. Twenty-two percent of the 
total subjects failed on ARB therapy. 
 In summary, HF clinic patients were prescribed a regimen of medications that 
follow the American College of Cardiology and the American Heart Association practice 
guidelines with a higher percentage of use of beta blockers, potassium sparing 
diuretics, and ARB’s. The physician office group had a higher percentage of prescribed 
aspirin and ACE inhibitor therapy. 
 Co-morbid conditions in the HF subjects (Table 5) showed some significant 
differences between the two groups. Cardiomyopathy was found in 86.6% of the HF 
clinic subjects and 30% of the physician practice subjects and was significantly different 
(p=<.001) between the two groups. There was with an overall cardiomyopathy rate of 
58.3% in total subjects. A listed diagnosis of angina was found in 38.3% of the total 
subjects. The HF clinic group had an incidence of 6.7% and the physician practice an 
incidence of 70% and there was a significant difference (p= <.001) between the two 
groups. Coronary artery disease was found in 50% of the HF clinic group and 93.3% in 
the physician practice group (p= <.001) and the differences between the two groups 
was highly significant. Implanted cardiac defibrillators were found in 66.7% of the HF 
clinic group and 16.7% in the physician practice group and the differences between the 
two groups was significant (p=<.001). 
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Table 5: Co-morbidity Health Related Information in Subjects with Heart Failure 
 Multi-Disciplinary 
Disease 
Management HF 
Clinic 
n=30 
Physician Run 
Private 
Practices 
n=30 
Total Subjects 
n=60 
 Frequency (%) Frequency (%) Frequency (%) Chi-
square 
p 
Co-Morbidity      
Chronic Obstructive 
Pulmonary Disease 
6 (20) 7 (23.3) 13 (21.7) 0.10 .754 
Diabetes 17 (56.7) 15 (50) 32 (53.3) 0.27 .605 
Cerebral Vascular 
Accident 
2 (6.7) 1 (3.3) 3 (5) 0.35 .554 
Hypertension 25 (83.3) 25 (83.3) 50 (83.3)  <.001 1.0 
Cardiomyopathy 26 (86.7) 9 (30) 35 (58.3) 19.82  <.001 
Myocardial 
Infarction/Acute Coronary 
Syndrome 
11 (36.7) 20 (66.7) 31 (51.7) 5.41 .02 
Angina 2 (6.7) 21 (70) 23 (38.3) 25.45 <.001 
Coronary Artery Disease 15 (50) 28 (93.3) 43 (71.7) 13.87 <.001 
Cardiac Stent 6 (20) 3 (10) 9 (15) 1.18 .278 
Coronary Artery Bypass 
Graph Surgery 
7 (23.3) 16 (53.3) 23 (38.3) 5.71 .017 
Dysrhythmias 16 (53.3) 23 (76.7) 39 (65) 3.59 .058 
Atrial Fibrillation/Flutter 13 (43.3) 11 (36.7) 24 (40) 0.28 .598 
Valvular Disease 18 (60) 18 (60) 36 (60) <.001 1.0 
Congenital Heart 0 1 (3.3) 1 (1.7) 1.02 .313 
Rheumatic Heart 1 (3.3) 2 (6.7) 3 (5) 0.35 .554 
Hyperlipidemia 19 (63.3) 23 (76.7) 42 (70) 1.27 .260 
Sleep Disorder 4 (13.3) 6 (20) 10 (16.7) 0.48 4.88 
Pacemaker 9 (30) 6 (20) 15 (25) 1.96 .375 
Internal Cardiac 
Debibrillator 
20 (66.7) 5 (16.7) 25 (41.7) 15.45 <.001 
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Coronary artery bypass graft (CABG) surgery was present in 23.3% of the HF 
clinic group and 53.3% of the physician practice group (p = .017). The overall CABG 
surgery rate in the total subjects was 38.3%. History of a myocardial infarction (MI) or 
acute coronary syndrome was 51.7% in the overall group. Approximately 37% of 
subjects in the HF clinic group had an incidence of MI as part of their history while 
66.7% of subjects in the physician office group had a MI documented (p = .02). 
 Dysrhythmias were listed as a co-morbidity in 39 (65%) of total HF subjects. In 
the HF clinic group 16 (53%) subjects were identified with dysrhythmias, while in the 
physician practice group 23 (77%) of subjects listed dysrhythmias as a medical 
problem. The difference between the groups did not reach significance (p = .058). The 
presence of atrial fibrillation or flutter as a dysrhythmia was queried. The HF clinic group 
had 13 (43%) subjects with this diagnosis and the physician practice group had 11 
(37%). There was no significant difference between the two groups (p = .598). 
 Information regarding documentation of the New York Heart Association (NYHA) 
classification for patients with HF was reviewed. NYHA classification was documented 
on 30 (50%) of the total sample of medical records (n=60). Two records (7%) in the HF 
clinic group (n=30) and 28 records (93.3%) in the physician practice group (n=30) had 
NYHA classification documented. The HF clinic group (n= 28) had 12 subjects (40%) 
with a Class I (least severe classification) designation, seven subjects (23.3%) had a 
Class II designation, three subjects (10%) Class III designation, and 6 (20%) subjects 
were designated Class IV (most severe classification). The physician practice group 
(n=2) had zero Class I and II, one (3.3%) Class III, and 1 (3.3%) Class IV patient. 
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 Documentation of the type of HF (systolic, diastolic, combined) was reviewed. 
This information was documented on 21 (35%) out of the total medical records (n=60) 
reviewed which included 16 (53.3%) of the HF clinic group records and 5 (16.6%) of the 
physician practice group records. The HF clinic group had 12 (40%) subjects with 
systolic HF, two (6.7%) subjects with diastolic HF, and two (6.7%) subjects had a 
combination of the two types. The physician practice group totaled four (13.3%) 
subjects with systolic HF and one (3.3%) subject with diastolic HF. 
 In summary, there were significant differences in demographics between the two 
treatment locations. The HF clinic subject group was younger, single, more highly 
educated, traveled longer distances to their appointment, and have had HF less number 
of years. The HF clinic group had poorer heart function at initiation of treatment and with 
treatment, less incidence of dysrhythmias but more device treatment for the 
dysrhythmias identified. The HF clinic group had a higher incidence of cardiomyopathy 
as a cause for HF while the physician office group had a higher incidence of coronary 
artery disease and myocardial infarction. 
 B. Reliability of Study Tools 
 Reliability statistics for this study sample were completed on two of the three 
tools used in this study. Reliability, the extent to which measures give consistent or 
accurate results, was calculated using SPSS software. The sub-scale scores of the 
Minnesota Living with Heart Failure Questionnaire (MLHFQ) and the Self Care 
Resource Inventory (SCRI) tools used in this study had acceptable Cronbach Alpha’s 
that demonstrated internal consistency and reliability (Table 6). 
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Table 6: Cronbach Alpha Statistics for the Study Population 
Questionnaire Sub-Scales Number of Items Cronbach Alpha 
MLHFQ1  Physical Scale 8 .88 
MLHFQ1  Emotional Scale 5 .77 
SCRIN2  Internal 12 .91 
SCRIN2  External 7 .83 
SCRIA3  Internal 12 .89 
SCRIA3  External 11 .86 
 
1 MLHFQ - Minnesota Living with Heart Failure Questionnaire 
2 SCRIN - Self Care Resource Inventory Needs 
3 SCRIA - Self Care Resource Inventory Availability 
 
 
The MLHFQ physical sub-scale had one item, question number 6, “Making your 
working to earn a living difficult” with an item total correlation of less than .35. Because 
of the age of the study subjects this question was not as applicable. It was included as 
this tool has been used extensively in the HF population and has shown good overall 
reliability in other published studies. The MLHFQ emotional sub-scale item total 
correlations were all greater than .35. 
 In three of the four sub-scales of the SCRI there was one question with an item 
total correlation below the .35 value. The Self Care Resource Inventory Needs (SCRIN) 
internal sub-scale and the Self Care Resource Inventory Availability (SCRIA) internal 
sub-scale had the same question that scored less then .35 for the item total correlation. 
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This was identified as question number 3, “Information about my illness and treatment”. 
Despite the low level of internal consistency on this one item, the question was retained. 
One possible reason for the low correlation was that the subjects felt they had received 
enough information. In the SCRIA external sub-scale question number 20, “Assistance 
so I can do my work or usual activities”, also had an item total correlation below .35. In 
consultation with the questionnaire author, the question was retained because it did not 
strongly influence the overall questionnaire quality. 
 The third tool, the Short Form-36v2 (SF-36v2), has been used extensively in the 
literature and published reliability statistics with the HF population. Reliability 
coefficients ranging from .78 to .92 are published for the specific HF population and the 
Short Form-36 (SF-36) tool (Ware, Kosinski, & Gandek, 2000). Items are weighted in 
the development of each scale and this makes calculation of a Cronbach Alpha difficult 
to perform and interpret. Therefore a Cronbach Alpha was not determined for this tool. 
 C. Results by Question 
 Research Question 1 
 Does health related QOL differ among patients with HF who are receiving 
medical outpatient care in two different clinical settings: a multi-disciplinary (nursing, 
medicine, pharmacy, physical therapy, social work, nutrition) disease specific HF clinic 
and physician run private practices as measured by the Medical Outcomes Study SF-
36v2 using the Physical Component Summary Scale (PCS) and the Mental Component 
Summary Scale (MCS)? 
 Table 7 outlines the results of the SF-36v2 questionnaire in these HF subjects.  
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Table 7: Health Related Quality of Life as measured by the Short Form-36v2 in    
Subjects  with Heart Failure  
 
SF-36v2 
Health Survey 
Scores 
Multi-Disciplinary 
Disease 
Management HF 
Clinic 
n=30 
Physician Run 
Private Practices 
n=30 
Total Subjects 
n=60 
  
 Mean SD Mean SD Mean SD t test p 
Physical 
Component 
Summary 
Score 
35.7 9.4 36.0 9.1 35.8 9.2 0.14 .889 
Mental 
Component 
Summary 
Score 
47.5 9.5 43.2 11.8 45.3 10.8 -1.5 .135 
         
Physical 
Functioning 
35.7 9.8 34.1 11.0 34.9 10.4 -0.59 .551 
Role-Physical 36.1 11.4 34.2 11.0 35.1 11.2 -0.67 .501 
Bodily Pain 49.0 11.4 44.9 11.8 46.9 11.7 -1.4 .183 
General 
Health 
33.2 9.4 36.7 8.9 34.9 9.2 1.50 .142 
Vitality 36.4 12.5 35.3 11.8 35.9 12.1 -0.33 .741 
Social 
Functioning 
44.7 12.2 44.3 10.9 44.5 11.5 
 
-0.12 .904 
Role-
Emotional 
47.9 10.4 39.4 13.1 43.7 12.5 -2.8 .007 
Mental Health 45.0 11.9 42.8 13.6 43.9 12.7 -0.68 .498 
 
1 QOL - Quality of Life 
2 SF-36v2 - Short Form - 36 version 2 Health Survey 
3 HF - Heart Failure 
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No significant differences between the two groups were found on the PCS (p = 
.889) or the MCS (p = .135). The mean scores of the PCS were virtually equal, the HF 
clinic group mean score was 35.7 and the physician office group was 36.0 with a total 
subject mean of 35.8.  
The PCS summary score measures physical limitations, energy levels, and pain. 
The MCS mean score in the HF clinic group was 47.5 and in the physician office group 
was 43.2 with an overall mean of 45.3. The MSC summary score measures 
psychological distress and limitations in social roles due to emotional problems (Ware et 
al., 2000). 
 Of the eight sub-scores (physical functioning, role-physical, bodily pain, general 
health, vitality, social functioning, role-emotional, and mental health) only the role-
emotional sub-score showed a significant difference (p = .007) between the two groups. 
The mean score in the HF clinic group was 47.9 and the in the physician office group 
the mean score was 39.4 with an overall subject mean of 43.7. The role emotional sub-
score measures problems with work or other daily activities as a result of emotional 
problems (Ware et al., 2000). 
 Based on the research question, there were no significant differences in the 
physical or mental health summary scales between the two groups. Of the eight sub-
scale scores of the SF-36V2 tool, there was a significant difference in only one sub-
scale score, the role-emotional score between the two groups. The role emotional score 
defines substantial differences in mental health burden and the score was significantly 
lower in the physician practice group. Health related QOL was scored similarly in both 
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groups which could indicate health related QOL is not effected by the treatment 
location. 
 Research Question 2 
 Does disease specific QOL differ among patients with HF who are receiving 
medical outpatient care in two different clinical settings:  a multi-disciplinary disease 
specific HF clinic and physician run private practices as measured by the MLHFQ total 
score, physical sub-score, and emotional sub-score? Table 8 presents the scores on 
the MLFHQ. 
 
Table 8: Disease specific Quality of Life as Measured by the MLHFQ1 in Subjects with 
Heart Failure  
 
MLFHQ Scores Multi-Disciplinary 
Disease 
Management HF 
Clinic 
n=30 
Physician Run 
Private Practices 
n=30 
Total Subjects 
n=60 
 Mean SD Mean SD Mean SD t test p value 
Total Score 46.4 24.7 47.2 23.5 46.8 23.9 0.12 .907 
Physical 
Dimension 
19.6 11.0 19.3 10.5 19.5 10.7 -0.131 .896 
Emotional 
Dimension 
10.4 6.9 10.5 6.3 10.4 6.6 0.06 .953 
 
1 MLHFQ - Minnesota Living with Heart Failure Questionnaire 
 
 
 There were no significant differences in the values of the MLHFQ total scores (p 
= .907) between the two groups. The mean total scores in the two groups were virtually 
equal, the HF Clinic group mean total score was 46.4 and the physician office group 
was 47.2. The physical dimension sub-score was not significantly different (p = .896). 
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The HF Clinic group physical sub-score was 19.6 and the physician practice group was 
19.3. The emotional dimension sub-score did not show significant differences (p = .953) 
between the two groups. The HF Clinic group emotional dimension sub-score was 10.4 
and the physician practice was 10.5.  
 Based on the research question disease specific QOL was scored the same in 
the two treatment groups. There was no significant difference in disease specific QOL in 
any of the MLHFQ total or sub-scores among patients with HF who receive medical 
outpatient care in the two different clinical settings. 
 Research Question 3 
 Are there differences in self care resources of patients with HF that are receiving 
medical outpatient care in two different clinical settings, a multi-disciplinary disease 
specific HF clinic and physician run private practices as measured by the SCRI and the 
sub-scales SCRIN and SCRIA scores? Table 9 presents the scores on the SCRI 
questionnaire. 
 The SCRIN sub-score measures what the patient needs to help them deal with 
their illness and get better. The SCRIA sub-score measures what the patient has 
available to them to deal with their illness The internal sub-score measures factors that 
make the individual unique such as hope, control, self-efficacy, and future orientation. 
The external sub-score measure those factors which are separate from the individual 
such as social support, social network, financial assistance, health care provider 
support, and help with daily activities such as driving and shopping. 
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Table 9: Self Care Needs as Measured by the SCRI1 in Subjects with Heart Failure 
SCRI Scores Multi-Disciplinary 
Disease 
Management HF 
Clinic 
n=30 
Physician Run 
Private Practices 
n=30 
Total Subjects 
n=60 
 Mean SD Mean SD Mean t test p 
value 
SCRIN2        
Internal 35.4 6.6 40.3 5.8 37.8 3.047 .003 
External          15.4 5.8 22.5 4.6 18.9 5.187 <.001 
SCRIA3        
Internal 32.9 8.1 35.9 9.3 34.5 1.318 .193 
External 27.6 7.40 33.1  8.5 30.4 3.015 .004 
 
1 SCRI - Self Care Resource Inventory 
2 SCRIN - Self Care Resource Inventory Need 
3 SRNIA - Self Care Resource Inventory Availability 
 
 The HF clinic group overall scored lower on all aspects of the SCRI questions. 
Three of the four sub-scale scores were significantly different between the two groups. 
Both the internal (p = .003) and external (p=<.001) SCRIN sub-scores were significantly 
different. The internal and external resources measured by the SCRIN were significantly 
lower in the HF Clinic group than the physician run practice. Needs were also measured 
by the number of clinic/office appointments and hospitalizations within the past 12 
months. 
 The number of clinic/office appointments between the two groups was 
significantly different (p = .005).  The HF clinic group averaged 5.5 visits per 12 months 
and the physician office group averaged 3 visits. There was a larger range in the 
number of clinic/office appointments between the two groups with the HF clinic group 
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ranging from one to 25 and the physician office ranging from one to six visits. 
 The number of hospitalizations in the past 12 months was significantly different 
between the two groups (p = .017). The HF clinic group had a mean of two (range of 
zero to 16) and the physician office group had a mean of less than one (range of zero to 
three). 
 The external (p = .004) SCRIA sub-score also showed significance. The external 
resource scores were significantly different with the HF clinic group scoring lower in 
both the SCRIN and SCRIA scores. Availability was also measured by the number of 
phone calls the subject made to the clinic/office within the past 12 months. There was 
no significant difference between the two groups (p =.136). The HF clinic group 
averaged three calls per 12 months (range zero to 40) and the MD office group 
averaged less than one (range zero to six). 
 There are significant differences in the internal and external needs and external 
availability of self care resources of patients with HF that are receiving medical 
outpatient care in two different clinical settings. Patients in the HF clinic group showed 
lower internal resource needs and availability and lower external resource availability. 
What an individual needs and what is available to deal with their illness was different 
between the two treatment groups. 
 D. Descriptive Questions 
 Two open ended descriptive questions were asked of all subjects in this study. 
Results are presented in Table 10. 
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Table 10: Subject Answers to Open Ended Questions 
“How do you define 
or describe heart 
failure?” 
Multi-Disciplinary 
Disease 
Management HF 
Clinic 
n=30 
Physician Run 
Private 
Practices 
n=30 
Total Subjects 
n=60 
Chi-
squar
e 
p 
Pain 6 (20%) 8 (27%) 14 (23%) .37  .542 
Shortness of 
breath 
13 (43%) 13 (43%) 26 (43%) .00   1.0 
Weakness 4 (13.3%) 10 (33.3%) 14 (23%) 3.4 .067 
Tired 7 (23%) 5 (17%) 12 (20%) .42 .519 
Scary 1 (3%) 0 1 (2%) 1.0 .313 
      
“What does heart 
failure mean to 
you?” 
     
Dying 1 (3%) 3 (10%) 4 (7%) 1.1 .301 
Scary 2 (7%) 1 (3%) 3 (5%) .68 .410 
Slow down 15 (30%) 16 (53%) 31 (52%) .35 .554 
Do Less - Can’t 15 (30%) 10 (33.3%) 25 (42%) 1.7 .190 
Tired 2 (7%) 1 (3%) 3 (5%) .35 .554 
Changed my life 5 (17%) 12 (40%) 17 (28%) 4.0 .045 
 
 
 The first question asked was “How do you define or describe heart failure?”. 
Shortness of breath or not being able to breathe was verbalized 43% of the time in each 
group. There was no significant difference between the groups (p = 1.0). Weakness was 
described more in the physician office group (33.3%) as opposed to the HF Clinic group 
(13.3%) and was found to approach significance (p = .063). 
Pain was also described by 20% of the HF group and 27% in the physician office as the 
definition of HF with no significant differences between the groups (p = .542). 
  
90
 The second question asked was “What does heart failure mean to you?”. Fifty 
three percent of the subjects in the physician office group and 30% in the HF Clinic 
group answered “slowing down”, with no significant differences between the groups (p = 
.554). The verbalization of doing less or can’t do as much was about equal in the two 
groups, 30% in the HF Clinic group and 33.3% in the physician office group with no 
significant difference (p = .19). There was a significant difference in the responses 
“changed my life” (p = .042) with the HF Clinic group responding as such 40% (12) of 
the time and the physician office group 17% (5) of the time. 
 E.  Summary 
 Demographic and health related demographic data showed significant 
differences between the two groups. Physical QOL was not significantly different 
between the two groups. Emotional QOL as measured by the role emotional SF-36v2 
sub-scale score showed significant difference between the two treatment groups. Self 
care resources showed significant difference between the two treatment groups. 
Verbalization of HF “changed my life” was higher in the physician office group. 
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 V. Discussion 
 This chapter will discuss the conclusions and implications of the research results. 
Demographic results and the results of the research questions will be discussed. 
 A. Results 
 Demographics 
 This sample is specific to the population surveyed and may not represent the 
overall population of HF patients. Based on the study results, the patients being 
managed in the heart failure (HF) clinic were significantly younger than those patients 
being managed in the physician practice group. Based on age range the youngest 
subject in the study was in the HF clinic and the oldest subject was in the physician 
practice group. Compared to a study of Medicare beneficiaries in the county in which 
the HF clinic was located, this study group had fewer subjects over the age of 80 than 
the Medicare study (Wellenius, Bateson, Murray, & Schwartz, 2005). The reported 
mean age of patients in this study group was lower than the mean age in the Acute 
Decompensated Heart Failure National Registry (ADHERE) database at 75.1 (ADHERE 
Registry, 2004). The rate of subjects over the age of 75 was lower in the HF clinic group 
and higher in the physician office group than the ADHERE database at 47%. The 
percentage of subjects under age 50 was lower in the physician practice group and 
higher in the HF clinic group. This emphasizes the disparity in ages between the 
groups. One possible reason for this disparity is that younger patients may be seeking 
more aggressive treatment available at the HF clinic. 
 Gender was not significantly different between the two groups and compared to 
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the ADHERE database (52% males and 48% females). This sample included more 
males and less females than the ADHERE database (ADHERE Registry, 2004). One 
reason for this disparity might be the convenience sampling used in this study.  
 The subjects in this study were predominately Caucasian. There was no 
significant difference between the Caucasian and African American groups, but the HF 
clinic group had more African American subjects than the physician practice group. It is 
published that approximately 23% of patients with HF are African American (Klein et al., 
2003). In the population studied the percentage of African Americans in the physician 
practices was below this benchmark, but was higher in the HF clinic group. This may be 
attributed to the larger catchment area the clinic serves. Compared to the ADHERE 
database data the total population in this study had a higher percentage of Caucasian 
subjects (15% higher than in the ADHERE database) and a lower percentage of African 
American subjects (8% lower than in the ADHERE database) which indicated that this 
population is not equivalent to the ADHERE database norms. There were no Asian or 
Hispanic subjects in this convenience sample. The American Heart Association 
statistics state that 2.7% of male and 1.6% of female Hispanics are diagnosed with HF 
(2006 Heart and Stroke Statistical Update, 2005) and the ADHERE database HF 
benchmarks three percent Hispanics and one percent Asians (ADHERE Registry, 
2004). Because this was a convenience sample, the lack of Hispanic and Asian 
subjects can be partially attributed to the convenience population and represented the 
demographics of the community in which the study was conducted. 
 The HF clinic group included more subjects who had completed higher education 
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(graduated two or four year college) and this finding was significant. The physician 
office group had a larger number of subjects at both extremes in education. Eleven had 
not completed a high school education and four of the subjects had completed graduate 
or post-graduate school. This disparity also continued in overall higher education with a 
higher percentage of subjects in the HF clinic group completing high school or post high 
school education. This inquiry did not have a follow-up survey question. An assumption 
might be made that subjects education could effect the ability to seek innovative 
medical care outside of their immediate geographical area. Subjects in the HF clinic 
group were better educated at both the high school and post high school levels. In 
summary they were better educated and thus may have better able to seek out 
additional treatment locations and treatments. 
 This finding could relate to the distance question. The subjects in the HF clinic 
group traveled a significantly higher number of miles to appointments. The physician 
office subjects traveled less miles to an office appointment. Number of miles traveled to 
appointments were almost double for HF clinic subjects with 150 being the most miles 
traveled for the HF clinic group. The HF clinic group were younger and possibly not as 
dependent on transportation to appointments making their increased travel distance 
manageable. 
 The length of HF diagnosis between the two groups in this study was not 
significant. The average length of HF diagnosis from initial onset to death in the 
literature is five years (2006 Heart and Stroke Statistical Update, 2005). Both groups 
exceeded this length of time and ranges were almost identical. Although the HF clinic 
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group had a higher acuity and a more severe physiological response to the disease, 
length of disease was not significantly different. There was the possibility of memory 
error as the question “How long have you known of your HF diagnosis?”, was answered 
by the subjects based on their recollection. Another possible contributing factor to 
question error was that subjects (23%) related pain to their HF diagnosis which could 
possibly confuse their HF diagnosis with myocardial infarction diagnosis. 
 The HF clinic had more subject hospitalizations in the past year, but the 
difference between the two groups was not significant. There was a wide range in the 
number of hospitalizations with the HF clinic having a higher number of hospital visits 
than the physician office group. The HF clinic group was sicker with an overall lower EF 
which could contribute to HF decompensation. While the literature supports the position 
that disease specific clinics decrease the number of hospitalizations per year 
(Hershberger et al., 2001) this premise is not supported with this study’s subject group. 
 While the number of emergency room visits was also higher in the HF clinic 
group, there was not a significant difference between the two groups. The range in the 
number of visits was greater in the HF clinic group. This could be due to the younger 
age, higher acuity of problems requiring treatment for acute decompensation, and co-
morbidity problems. 
 The number of phone calls for health services in the past 12 months was higher 
in the HF clinic group. The range of phone calls was greater in the HF clinic group. 
There was no follow-up inquiry for this question in the survey to investigate the reasons 
for the calls (development of new or increasing symptoms, weight gain, medication 
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adjustment, or clarification of instructions). 
 There was not a significant difference in the mean number of physician/clinic 
visits per year between the two groups although the HF clinic group did have a slightly 
higher number of visits and the range was greater. This may be attributed to the age of 
the subjects, need for adjustments in therapy, and acuity of illness. The total number of 
physicians seen by patients was the same in both groups. 
 The initial ejection fraction (EF) was lower by almost half in the HF clinic group. 
This was a highly significant difference between the groups. The HF clinic group was 
not only younger, but their cardiac status was more compromised at the initiation of HF 
treatment. EF the HF clinic group decreased more since their initial visit. This would 
indicate that even with aggressive treatment in either setting, EF as a measure of 
cardiac function continues to decrease over time. In this study the EF was documented 
in 100% of the medical records. In the ADHERE database the EF was only documented 
85% of the time (ADHERE Registry, 2004). 
 This self report of medications that the patient was taking versus information 
about medications the patient was on from the medical record differed in number in both 
groups. In the total sample, the medical record recorded one to five more medications 
listed than the self report of subjects. The HF clinic group had a higher number of 
discrepancies meaning the subject self report of medications taken and the medical 
record report of what the patient was taking were not consistent. Both groups showed 
discrepancies between self report and the medical record. In some cases there were as 
many as five medications that were not self reported by the patient but were listed on 
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the medical record. This could have an effect on the patient outcome in two ways. The 
patient could be taking medications that the health care provider is not aware of which 
could lead to adverse drug interactions. It is also possible that the patient may not be 
taking all medications prescribed by the health care provider and the treatment outcome 
may be altered. The importance of medication reconciliation in the outpatient setting is a 
high priority in overall care. The Joint Commission on Accreditation of Healthcare 
Organizations 2006 National Patient Safety Goals specifically addresses medication 
reconciliation in all health care settings. The findings in this study highlight the 
opportunity for error in this setting. 
 The category of HF medications was assigned by the researcher after review of 
the list of patient medications based on the American College of Cardiology and the 
American Heart Association (AHA) guidelines (Hunt et al., 2001). There was no 
significant difference in beta blocker use between the two groups and the percentages 
of both groups exceeded the 77% benchmark in the AHA statistics (2006 Heart and 
Stroke Statistical Update, 2005) and 74% in the ADHERE database (ADHERE Registry, 
2004). Prescription of angiotensin receptor blockers (ARB’s) was significantly different 
between the two groups as was the prescription of angiotensin converting enzyme 
(ACE) inhibitors. When the two medication groups are combined and the subject is 
either on an ARB or ACE inhibitor, the overall prescription rate in the private physician 
office group and in the HF group is congruent with the AHA statistics for HF (2006 Heart 
and Stroke Statistical Update, 2005) and the ADHERE database at 68% (ADHERE 
Registry, 2004). This could indicate that the guidelines are known and being 
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implemented in these treatment settings. 
 Diuretic use is a mainstay of therapy with patients with HF. Overall diuretic use 
was documented in the ADHERE database subjects 88% of the time. In this study the 
percentage was slightly lower. The specific use of potassium sparing diuretics was 
higher in this study in both groups in contrast to the ADHERE database (7%) with the 
HF clinic significantly higher. This would indicate a tendency to adhere to the latest HF 
guidelines regarding diuretic therapy. This form of diuretic also necessitates closer 
monitoring of electrolytes and fluid status which correlates with the increased number of 
clinic visits and phone calls. 
 Aspirin prescription was higher in the private physician practice group than the 
HF clinic group. There was a significant difference between the two groups. Aspirin or 
some form of anticoagulation is recommended in the American College of 
Cardiology/American Heart Association guidelines when atrial fibrillation or mechanical 
valve replacement is present. While aspirin is not a Class I recommendation (there is 
evidence that treatment is beneficial, useful, and effective), cardiovascular guidelines 
advocate the administration of aspirin (Hunt et al., 2001). Both groups had a higher 
percentage of aspirin use than in the ADHERE database (ADHERE Registry, 2004). 
 A review of the co-morbid conditions in the subjects showed a significant 
difference with some diagnoses. Cardiomyopathy was significantly different between the 
two groups  with a rate of almost 3:1 in the HF clinic group when compared to the 
physician office group. Causes for cardiomyopathy may differ between the two groups 
due to age. Drug abuse and viral myocarditis/endocarditis can contribute to the 
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diagnosis in younger patients while coronary artery disease and hypertension are often 
identified as the cause in older patients. The disparity in rate may be due in part to the 
younger age of subjects in the HF clinic group and the inclination to seek out additional 
treatment options. 
 Coronary artery disease was significantly different between the two groups with 
the private physician practice having a higher incidence. The percentage in the HF clinic 
group was lower than in the ADHERE database, while the private physician practice 
group was higher. Myocardial infarction or acute coronary syndrome was significantly 
different between the two groups with the physician office group having a higher 
percentage of subjects with this diagnosis. The HF clinic group had a lower percentage 
than in the ADHERE database and the physician office group had a higher percentage. 
There was a significant difference between the two groups regarding angina. In the 
physician office group a higher percentage of subjects had a history of angina and in the 
HF clinic group the percentage of angina was much lower. This could be a 
documentation issue regarding past medical history on the medical record (ADHERE 
Registry, 2004). Age could also be a factor. The older age in the physician office group 
could explain the increased incidence of coronary artery related disease in this group. 
There was not a significant difference in hypertension diagnosis between the two 
groups and hypertension was higher in both treatment groups than the ADHERE 
database (ADHERE Registry, 2004).  
 The presence of dysrhythmias was significantly different between the two groups. 
The physician office group had more documented dysrhythmia diagnoses. The 
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presence of an internal cardiac defibrillator (ICD) was significantly higher in the HF clinic 
group. Four times as many patients had ICDs in the HF clinic group than the private 
physician practice group. The overall percentage was slightly higher than in the 
ADHERE database. The presence of a pacemaker was not significantly different 
between the two groups, but the HF clinic group had a higher percentage of devices. 
Atrial fibrillation/flutter was not significantly different between the two study groups but 
was found to be present at a higher rate than in the ADHERE database (ADHERE 
Registry, 2004). While fewer dysrhythmias were found in the HF clinic, more device 
treatment with ICDs and pacemakers was initiated for those dysrhythmias, hence more 
aggressive treatment. 
 A diagnosis of diabetes was not significantly difference between the two study 
groups but was found at a higher percentage in both groups than in the ADHERE 
database at 44%. Sleep disorders was not a co-morbid condition included on the past 
medical history list. Due to the initial number of subjects indicating sleep problems, the 
question was asked of each subsequent subject. This condition was found in about 25% 
of the subjects, but no significant difference was found between the two groups. 
 There was a significant difference in the documentation of the New York Heart 
Association (NYHA) classification and the type of HF between the two groups. These 
findings may be skewed because of documentation inconsistencies. The HF clinic group 
medical records showed a markedly higher percentage in the documentation of this 
information. This may in part be due to the standardized forms used for each visit. 
There is a designated place for documentation of NYHA classification and HF type on 
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the form. The private physician office documentation was obtained via dictated progress 
notes with no specific format. 
 There were significant differences in demographics between the two groups. 
Age, marital status, education and travel distance to appointment were found to be 
different between the two groups. Health related demographics were also significantly 
different. The HF clinic group was younger, sicker, had poorer heart function at the 
initiation of treatment and with treatment, had less dysrhythmias but more aggressive 
device treatment for the dysrhythmias identified, and had a higher incidence of 
cardiomyopathy as a cause of HF. 
 Research Question 1 
 Research question number one asked: Does health related QOL differ among 
patients with HF who are receiving medical outpatient care in two different clinical 
settings: a multi-disciplinary (nursing, medicine, pharmacy, physical therapy, social 
work, nutrition) disease specific HF clinic and physician run private practices as 
measured by the Medical Outcomes Study Short Form 36v2 Health Survey (SF-36v2) 
using the Physical Component Summary Scale (PCS) and the Mental Component 
Summary Scale (MCS)? 
 There were no significant differences between the two groups in the two SF-36v2 
summary scores and seven of the eight sub-scores. Physical status as a measure of 
physical functioning and well-being is measured by the PCS summary score and was 
rated the same in both groups. Both group scores in this study were slightly higher than 
the norm SF-36v2 data for HF patients. This could indicate a slightly higher physical 
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status due to subject age and their ability to provide self care activities. The MCS 
summary score, measuring social and role disability due to emotional problems, showed 
no significant difference between the two groups, however both groups scored slightly 
lower than the norm SF-36v2 data for HF patients (Ware et al., 2000). This could 
indicate a slight problem with social interactions and role activities due to health, 
specifically because of HF limitations. Both group summary scores were slightly 
different than the SF-36v2 norms, but virtually equal indicating no differences in physical 
or mental  functioning between the two groups. 
  Comparing the eight study sub-score results with the norms from the SF-36v2 
norm based data for HF, the study sub-scores were all lower than the norms except for 
role physical which was equivalent (Ware et al., 2000). The role-emotional sub-score 
was significantly different between the two groups. This score measures a problem with 
work or other daily activities as a result of emotional problems. 
  The HF clinic group scored significantly lower than the physician office group. 
This means that the subjects in this group were experiencing problems in completing 
self care activities at home or job responsibilities at work due to emotional issues 
related to HF. This could encompass financial worries, work productivity issues, or 
attendance issues. The HF clinic group could have scored lower due to the overall 
younger age of this subject group. The HF clinic group is predominantly of working age 
and work related issues would be more prevalent in this group. 
 The Jenkinson, Jenkinson, Sheppard, Layte, and Peterson (1997) study used the 
SF-36 in patients with HF receiving an experimental angiotensin converting enzyme 
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(ACE) inhibitor. The tool was administered before initiation of treatment and at four 
weeks. All of the summary and sub-scores in this study were lower than in the 
Jenkinson et al. (1997) study and the SF-36v2 HF data norms indicating that the QOL 
was lower in this population. 
 Differences in this sub-score between the groups may be attributed to the 
differences in ages of the two groups. Being younger, the HF clinic group may have 
more issues with work such as attendance and productivity. Being older, the physician 
office group may have more issues with daily activities such as driving and shopping. 
Although emotional diagnoses were not initially tabulated, a second review of the data 
was conducted and two subjects in the physician office group and three subjects in the 
HF clinic group had a documented diagnosis of depression on the medical record. 
Subject generated medical history did not list depression diagnoses in either group. A 
review of the medication lists revealed that seven subjects in the physician office group 
and five subjects in the HF clinic group were prescribed antidepressants. This disparity 
in listed diagnosis and medication treatment in the medical record indicates a need for 
medication diagnosis reconciliation. 
 The various SF-36v2 sub-scores in both groups indicated a poorer health related 
QOL when compared to the HF norm. There were no significant differences in overall 
physical or mental health related QOL between the two groups, although the 
demographics in the two groups were significantly different. There was a significant 
difference in the role-emotional sub-score related to work, daily activities, and emotional 
problems with potential age related issues in both groups. 
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 Research Question 2 
 Research Question 2 : Does disease specific QOL differ among patients with HF 
who are receiving medical outpatient care in two different clinical settings: a multi-
disciplinary disease specific HF clinic and physician run private practices as measured 
by the Minnesota Living with Heart Failure Questionnaire (MLHFQ) total score, physical 
sub-score, and emotional sub-score? There was no significant difference in the total 
MLHFQ score, or the physical or emotional sub-scores between the two groups. 
 The MLFHQ total scores in this study were comparable to other HF studies using 
this tool at baseline (many of the studies administered the tool at baseline and at a 
designated time in the future). Rector’s initial study (Rector, Kubo et al., 1987) with HF 
patients reported a MLHFQ total score of 34. The subjects in this study were congruent 
with demographics in the Rector et al. (1987) study, but the EF was slightly lower  
indicating a slightly worse cardiac status. Ni et al. (2000), in a HF clinic setting, obtained 
a slightly higher total score. The sample was congruent with this study’s demographics 
(age, gender, education, ethnicity) and was sensitive to changes in QOL due to program 
interventions at the HF clinic. Riegel’s study (Riegel et al., 2003) comparing gender 
differences in a general HF population had a higher MLHFQ total score than in this 
study. Correlations due to gender were not compared in this study. There was 
congruence in age, EF, and martial status. Bennet had a much higher total score in the 
female HF population (S. J. Bennett, Baker, & Huster, 1998). Although demographics of 
other published studies were equivalent to the demographics in this study, scores of the 
MLHFQ in this study were higher indicating a poorer disease specific QOL. The higher 
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rating of disease specific QOL in this sample may be attributed to subject age, current 
EF, education, level of information, and  relationship with healthcare provider. 
 There was no significant difference between the two groups in the physical 
dimension sub-score with a difference of only .5 between the scores. The physical 
dimension sub-score of the MLHFQ correlated with the SF-36v2 PCS summary score. 
The physical dimension sub-scores in the Ni et al. (2000) and the Riegel study (2003) 
were all higher than the individual groups and overall study mean indicating a poorer 
disease specific QOL. The lower physical dimension sub-scores in this study (indicates 
a poor physical disease specific QOL) could be related to the lower age, lower current 
EF, subject co-morbidities, and gender. 
 There was no significant difference between the two groups in the emotional 
dimension sub-score. The emotional dimension sub-score correlated with the MCS 
summary score of the SV-36v2. The emotional dimension sub-score in the Ni et al. 
(2000) study and the Riegel et al. (2003) study were only slightly higher than in this 
study indicating the scores in this study are congruent with other studies. The 
importance of emotional QOL in patients with HF affects all aspects of daily life whether 
at work or at home and should be incorporated into treatment plans. The lower 
emotional dimension sub-scores in this study could be due to the convenience sample, 
subject age, number of co-morbidities, and level of family and healthcare provider 
support. 
 The disease specific QOL scores showed no significant difference between the 
two treatment locations. The physical and emotional sub-scores of the MLHFQ 
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correlated with the SF-36v2 scores. Disease specific QOL was not different in the two 
treatment locations. 
 Research Question 3 
 Are there differences in self care resources of patients with HF who are receiving 
medical outpatient care in two different clinical settings, a multi-disciplinary disease 
specific HF clinic and physician run private practices as measured by the Self Care 
Resource Inventory (SCRI) and the sub-scales Self Care Resource Inventory Needs 
(SCRIN) and Self Care Resource Inventory Availability (SCRIA) scores? 
 The study results indicated a significant difference between the two groups in 
three of the four sub-scores. The SCRIN measures what the patient needs to help them 
deal with their illness and get better.  The SCRIA measures what the patient has 
available to them to deal with their illness. The internal sub-score measures factors that 
make the individual unique such as hope and future orientation. The external sub-score 
measures those factors that are separate from the individual such as social support and 
health care provider support. 
 The internal and external SCRIN sub-scores measured what the subjects need to 
help them deal with their HF. There was a significant difference between the two groups 
in both the external and internal sub-scores. The HF clinic group scores indicated that 
this group had fewer unmet needs. The number of HF clinic appointments over a 12 
month period was greater than the number of physician office visits which can 
contribute to meeting the subject’s internal needs of hope, knowledge of HF, and 
treatment options. External needs could be met by HF clinic support, HF information, 
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and social support. The HF clinic group was younger, more educated, more hopeful, 
and had more of a future orientation. The physician office group had more identified 
needs, some of which are not being met. This group was older and had less of a future 
orientation.  
 External SCRIA sub-scores were significantly different between the two groups. 
The HF clinic group score indicates that this group had fewer needs and more of these 
needs or concerns were being met. The physician office group scores indicate that they 
had more identified needs and some were not being met. The HF group felt empowered 
to get their needs met, possibly due to the younger age of this group. They are able to 
obtain support from family and friends to accomplish this. When asked “Which person 
helps you at home the most to manage your HF?” spouse (wife or husband) was the 
most frequent answer in both groups. Wife was the most frequent answer to this 
question and this relates to the sample having a high percentage of males. One fourth 
of the subjects in both groups indicated “me” as the person that helped most to manage 
their HF. The scores of the physician office group indicate that support to meet their 
needs varies which leads to unmet needs. This group had fewer office visits, were older, 
and had less of a future orientation. 
 External SCRIA sub-scores also measure those factors which are separate from 
the individual such as social support and health care provider support and if those 
concerns are being met. The number of phone calls within a 12 month period was not 
significantly different between the two groups but the HF clinic group had a larger mean 
number and a larger range of calls. HF clinic subjects more readily called the clinic with 
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questions and concerns, had 24 hour access to both physicians and nurses, had more 
verbalized questions regarding their status, and got more direction and information 
regarding their HF diagnosis. The physician office group are older and may need more 
family support for daily activities. 
 While health related and disease specific QOL measures showed little 
differences between the two treatment locations, self care resources, what the individual 
needs and what is available to deal with their illness was significantly different. The 
importance of self care resources should be assessed by the health care provider to 
assist in meeting both the physical and emotional needs of the patient. Including this 
information in initial histories and individual visit questions can affect HF care. 
 Descriptive Questions 
 Words used to describe how the subjects defined HF and what it means were 
similar in both groups. The most common HF symptom, shortness of breath was the 
term used most frequently. 
 The most noteable phrase from the question responses was “changed my life”. 
There was a higher use of this phrase in the physician office group. Although the HF 
clinic group was younger and sicker it appears they were better able to adapt to 
changes in their life from HF. They adjusted to changes in physical status more easily. 
They perceived more support from both healthcare personnel and family/friends. The 
physician office group were older and had the opportunity to experience more loss. The 
changes in their life due to HF became more profound as they reflected on the number 
of activities they once were able to participate in and now cannot because of physical 
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limitations. Being able to play a round of golf, mow the yard, dance, shop at the local 
mall, or attend grandchildren sports events were all examples of activities that subjects 
were once able to do, and now were missing from their life. 
 In conjunction with the phrase changed my life, the terms cannot and slowed 
down were common themes in the subject responses. In many of the responses use of 
the word “can’t” was repetitive. The subjects associated their daily life with what HF 
meant to them and many of the responses were negative in the phrases verbalized from 
the point of what they couldn’t now do compared to what they were able to do in the 
past. 
 B. Significance to Nursing 
 The different care settings for the patient with HF affects the delivery of care.  
Research findings have shown decreased admission rates and decreased costs with 
disease specific HF clinic patient management 
(Harrison, Toman, & Logan, 1998; Paul, 2000; Rich et al., 1995; Rich et al., 1993). With 
decreased lengths of stay in acute care settings, the patient, in collaboration with their 
identified primary care provider must assume an active role in maintaining health and 
disease management. The different levels of health care providers (physician, nurse, 
advanced practice nurse, physician assistant) who provide medical management of a 
chronic illness such as HF can influence the care the patient receives. 
 Nurses can affect the quality of care the patient with HF receives. Whether the 
nurse is the primary care giver as with an advanced practice nurse or adjunct care giver 
in the office, clinic, hospital, or home, the nurse can affect how the patient views, 
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accepts, and manages their chronic disease on a daily basis. The personal interaction 
with the nurse at the beginning of the office/clinic visit can identify those self care 
resources that need to be addressed. After hour phone calls being answered by a nurse 
is another important aspect of care. The nurse can play an important role in continuity of 
care. This can influence the subsequent financial and emotional effect on the health 
care system. 
 From a financial aspect, the benefits of cost-effective care are evident. The 
health care system needs to address the increased cost and benefits in relation to the 
medical care setting chosen and its effect on patient QOL. While the financial 
ramifications of HF care from the third party payer aspect is important ("Humana CHF 
program cuts costs, admissions," 1998; Mark, 1997; Philbin & Roerden, 1997; Rich, 
1999) research also needs to address the patient’s QOL perspective. What has not 
been clearly addressed in the literature is the impact of the different medical 
management settings on the patient’s self-reported QOL. QOL assessments are 
important outcome measures in clinical research trials (Dracup et al., 1992; Konstam, 
2001; Packa, 1989; Tandon, Stander, & Schwarz, 1989). Prior to this study, research 
had not been conducted comparing QOL measurement as an additional outcome 
measure for different treatment locations. 
 In this study there were no significant differences in health related or disease 
related QOL between the groups in the two treatment locations. Although this finding 
showed no differences, it is important for inclusion in the literature about the 
measurement of QOL in those locations. Studies directly comparing QOL in different 
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treatment locations have not been conducted, therefore the findings of this study add to 
nursing knowledge. The monetary comparisons between treatment locations in prior 
studies show a marked positive financial effect for the disease specific management 
treatment location. This study has shown that QOL is not effected by the treatment 
location and that disease specific management locations can be cost-effective and 
maintain an adequate level of patient QOL. 
 Although this study sample was small, it indicates that health care provided in 
these two different treatment locations have similar endpoints when measuring QOL. 
Because of the small sample size these results may not be easily generalized to other 
samples. 
 Use of the MLHFQ and the SF-36v2 tools are well documented in the literature in 
the HF population. This study adds to that body of literature. Use of the SCRI tool is 
limited in the literature and therefore the results of this study will add to this literature. 
  C. Limitations of the Results/Study 
 Several issues related to the sample may limit the generalization of results. Not 
all medically managed HF situations were studied. This study chose two of many 
possible scenarios, an existing disease specific HF clinic based in a university setting 
and private physician practices in a non university setting. Other possible settings that 
could be studied would include: general family practice offices, internal medicine 
practices not specializing in cardiology, emergent settings (emergency department, 
urgent care settings) with patients who do not have a primary physician, hospitals for 
acute care management, home care, or an advanced practice nurse setting. While the 
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private physician practice is one of the more traditional methods of HF medical 
management, the clinic setting is now more mainstream. Published research focused on 
the above listed settings in isolation (Harrison et al., 1998; Paul, 2000; Rauh, 
Schwabauer, Enger, & Moran, 1999; Shah et al., 1998). This study compared two 
settings most commonly utilized by patients with HF, a disease specific HF clinic and 
private physician office. 
 Only one heart failure clinic treatment location was included. In this geographical 
area there are only two designated heart failure clinics and both clinics were 
approached regarding this study. Only one clinic allowed data collection to proceed. The 
second HF clinic stated that their patients were already involved in multiple research 
studies and an additional study at this time would be detrimental to patient care. There 
were many private physician offices with cardiology specialities in the geographical 
area. The two physician practices chosen for this study are established practices in their 
community. 
 The study population is small although sufficient power was reached. A 
convenience sample was obtained and this may be reflective of the total patient load of 
each treatment location. The study was done via face to face interviews. This had the 
advantage of not having any missed data as a review was conducted prior to the 
completion of the interview. A larger sample may have been obtained using a mailed 
questionnaire packet. This method can result in missing data thus the increased sample 
size may affect the results because of  missing data. 
 In comparing these treatment locations to current national benchmarks, it is 
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encouraging to validate that HF medication guidelines are being implemented. With this 
study not all database indicators were studied. It would be important to include those 
indicators (smoking cessation, initial and ongoing laboratory assessments, antioxidant 
therapy, documentation of hospital discharge instruction, weight, fluid management, and 
sodium restriction) in any future data collection. 
 Another limitation is the lack of standardization of the definition and composition 
of the HF clinic setting. Clinics have varied staffing, settings, resources, access to 
experimental and non-experimental interventions, and protocol management. Because 
of this, the HF clinic cannot be generalized from setting to setting without looking at the 
individual clinics in order to determine consistency. 
 Using a physician run private practice also has limitations. While all physicians 
completed medical rotations, there are differences in advanced education and practices. 
Education can vary from physicians completing an internal medicine residency to 
physicians completing specialized cardiology fellowships. Other differences in physician 
practices could include size of practice, number of additional physicians in the practice, 
disease management expertise, office hours, availability of interventional cardiology 
(coronary angioplasty, coronary stents) within the practice, in-office diagnostic testing, 
types of ancillary staff, and number of office staff. The physician practices studied in this 
research included two private physician practices with a primary cardiology specialty, in 
a non university, non teaching setting. The physician office environments and 
components were comparable. 
 An additional limitation is sample size. While the sample is representative of the 
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HF population, it is not a representative percentage of the HF population known to exist. 
Because of the small sample size, the results of this study may have limited application. 
 D. Future Directions 
 It would be important for this study to be replicated with a larger samples size 
using multiple treatment locations (home health, hospice, family practitioners, nurse 
practitioner clinics). An additional study that would correlate QOL measures in patients 
with HF to the nursing education levels in the different treatment locations could be 
beneficial in determining the value of advance practice nurses in HF settings. 
 Additional questions that could have been surveyed include: time spent in the 
office/clinic appointment, listing of other HF guideline interventions (smoking cessation, 
weight management, fluid management, dietary sodium restrictions), how the subject 
received information about the HF clinic (referring physician, nurse, family/friend 
recommendation, advertisement), work history/status, and drug and alcohol (including 
smoking) history. Mental health components (emotional health history, medication 
history) could be added to the medical history section.  
 Further research on self care resources is also needed. Questions concerning 
met and unmet needs of the patient with HF should be investigated. How information is 
obtained regarding patient issues and concerns is another area of further research. 
While this study recorded the number of phone calls for issues/problems, further 
information regarding time of day of the phone call, who the patient talked to (nurse, 
physician, answering service), and whether the issue/problem was resolved could be 
investigated. 
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 While the SF-36v2 was easy to administer, using the shorter SF-12 is a 
consideration in any subsequent studies. Having only 12 questions to answer is an 
advantage to subjects. The SF-12 reproduces the eight sub-scales and physical and 
mental summary scores using less questions and fewer levels. For large group studies 
these differences are not significant. If a smaller sample size is anticipated the SF-36v2 
may be the more precise instrument for health related QOL. 
 E. Summary 
 Although there were few significant differences in QOL measures in this study, 
future studies could clarify the differences identified and expand on the results of this 
study.  
 Important findings from this research focus on the differences found between 
these two groups. HF clinic patients were found to be younger and had poorer heart 
function at initiation of HF treatment and with ongoing HF treatment. This group was 
better educated, traveled longer distances to appointments, had a higher incidence of 
cardiomyopathy, and more device treatment for identified dysrhythmias. The physician 
office group was older, less educated, and had a higher incidence of coronary artery 
disease and myocardial infarction. This study identified that the differences in 
demographics and cardiac status between the two groups affect where HF medical care 
is located. 
 Health related physical QOL and disease specific QOL were not significantly 
different between the two groups. Mental health QOL as measured by the role-
emotional sub-score of the SF-36v2 was significantly different between the two groups. 
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The HF clinic group had utilized medical resources at a higher level (clinic visits, phone 
calls) than those in the physician office group. Self care resources were significantly 
different between the two groups and should be studied further. The study findings 
indicate that both locations are delivering quality, appropriate care HF care and that 
QOL is not effected by treatment location. 
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Appendix A: MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE  
These questions concern how your heart failure (heart condition) has prevented you 
from living as you wanted during the last month. The items listed below describe 
different ways some people are affected. If you are sure an item does not apply to you 
or is not related to your heart failure then circle 0 (No) and go on to the next item. If an 
item does apply to you, then circle the number rating how much it prevented you from 
living as you wanted. Remember to think about ONLY THE LAST MONTH. 
 
Did your heart failure prevent you from living as 
you wanted during the last month by: 
No Very 
Little 
   Very 
Much 
1. Causing swelling in your ankles, legs, etc? 0 1 2 3 4 5 
2. Making your working around the house or yard 
difficult? 
0 1 2 3 4 5 
3. Making your relating to or doing things with your 
friends or family difficult? 
0 1 2 3 4 5 
4. Making you sit or lie down to rest during the day? 0 1 2 3 4 5 
5. Making you tired, fatigued, or low on energy? 0 1 2 3 4 5 
6. Making your working to earn a living difficult? 0 1 2 3 4 5 
7. Making your walking about or climbing stairs 
difficult? 
0 1 2 3 4 5 
8. Making you short of breath? 0 1 2 3 4 5 
9. Making your sleeping well at night difficult? 0 1 2 3 4 5 
10. Making you eat less of the foods you like? 0 1 2 3 4 5 
11. Making your going places away from home 
difficult? 
0 1 2 3 4 5 
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Did your heart failure prevent you from living as 
you wanted during the last month by: 
No Very 
Little 
   Very 
Much 
12. Making your sexual activities difficult? 0 1 2 3 4 5 
13. Making your recreational pastimes, sports, or 
hobbies difficult? 
0 1 2 3 4 5 
14. Making it difficult for you to concentrate or 
remember things? 
0 1 2 3 4 5 
15. Giving you side effects from medications? 0 1 2 3 4 5 
16. Making you worry? 0 1 2 3 4 5 
17. Making you feel depressed? 0 1 2 3 4 5 
18. Costing you money for medical care? 0 1 2 3 4 5 
19. Making you feel a loss of self-control in your life? 0 1 2 3 4 5 
20. Making you stay in a hospital? 0 1 2 3 4 5 
21. Making you feel you are a burden to your family 
or friends? 
0 1 2 3 4 5 
 
Copyright University of Minnesota, 1986 
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Appendix B: SF-36v2 Health Questionnaire 
 
Instructions for Completing the Questionnaire 
Please answer every question. Some questions may look like others, but each one is 
different. Please take the time to read and answer each question carefully by filling in 
the bubble or circle that best describes your answer 
 
EXAMPLE 
This is for your review. DO not answer this question. The questionnaire begins with 
the section Your Health in General below. 
For each question you will be asked to fill in a bubble or circle in each line: 
 
1. How strongly do you agree or disagree with each of the following statements? 
 
 Strongly 
agree 
Agree Uncertain Disagree Strongly 
disagree 
a) I enjoy listening to music " " " " " 
b) I enjoy reading 
magazines 
" " " " " 
 
Please begin answering the questions below now. 
 
 Your Health in General 
 
1. In general, would you say your health is: 
Very 
Good 
Good Fair Poor  Excellent 
 
 " " " " " 
 
2. Compared to one year ago, how would you rate your health in general now? 
 Much better 
now than 
one year ago 
Somewhat 
better now 
than one 
year ago 
About the 
same as one 
year ago 
Somewhat 
worse now 
than one year 
ago 
Much worse now 
than one year ago 
 " " " " " 
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3. The following questions are about activities you might do during a typical 
day. Does your health now limit you in these activities?  Is so, How much? 
   Yes, 
Limited a lot 
Yes, Limited 
a little 
No, not limited at 
all 
a) Vigorous activities, such as 
running, lifting heavy objects, 
participating in strenuous sports 
" " " 
b) Moderate activities, such as 
moving a table pushing a vacuum 
cleaner, bowling, or playing golf 
" " " 
c) Lifting or carrying groceries " " " 
d) Climbing several flights of stairs " " " 
e) Climbing one flight of stairs " " " 
f) Bending, kneeling, or stooping  " " " 
g) Walking more than a mile " " " 
h) Walking several hundred yards " " " 
i) Walking one hundred yards " " " 
j) Bathing or dressing yourself " " " 
4. During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a result of 
your physical health? 
  All of the time Most of the time Some of 
the 
time 
A little 
of the 
time 
None of 
the time 
a) Cut down on the amount of time you  
spent on work or other activities 
" " " " " 
b) Accomplished less than you would like " " " " " 
c) Were limited in the kind of work or other activities " " " " " 
d) Had difficulty performing the work or other 
activities (for example, it took extra time) 
" " " " " 
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5. During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a result of 
any emotional problems (such as feeling depressed or anxious)? 
 All of the time Most of the time Some of 
the 
time 
A little 
of the 
time 
None of 
the time 
a) Cut down on the amount of time you spent on 
work or other activities 
" " " " " 
b) Accomplished less than you would like " " " " " 
c) Did work or other activities less carefully than       
usual 
" " " " " 
 
 
     
6. During the past 4 weeks, to what extent has your physical health or 
emotional problems interfered with your normal social activities with family, 
friends, neighbors, or groups? 
 Not at all Slightly Moderately Quite a bit Extremely 
 " " " " " 
   
7. How much bodily pain have you had during the past 4 weeks? 
None Very mild  Mild Moderate Severe Very Severe 
" " " " " " 
      
8. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)? 
 Not at all A little bit Moderately Quite a bit Extremely 
 " " " " " 
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9. These questions are about how you feel and how things have been 
with you during the past 4 weeks. For each question, please give the 
one answer that comes closest to the way you have been feeling. 
How much of the time during the past 4 weeks: 
 All of 
the 
time 
Most of 
the time 
Some of 
the time 
A little 
of the 
time 
None of 
the time 
a) did you feel full of       
life? 
" " " " " 
b) have you been           
very nervous? 
" " " " " 
c) have you felt so          
down in the dumps        
that nothing could          
cheer you up? 
" " " " " 
d) have you felt calm      
and peaceful? 
" " " " " 
e) did you have a lot of   
energy? 
" " " " " 
f) have you felt                
downhearted &              
depressed? 
" " " " " 
g) did you feel worn        
out? 
" " " " " 
h) have you been a        
happy? 
" " " " " 
i)  did you feel tired? " " " " " 
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10. During the past 4 weeks, how much of the time has your physical 
health or emotional problems interfered with your social activities 
(like visiting friends, relatives, etc)? 
  All of the 
time 
Some of 
the time 
A little 
of the 
time 
None of 
the time 
  " " " " 
11. How TRUE or FALSE is each of the following statements for you? 
  Definitely 
true 
Don’t 
know 
Mostly 
false 
Definitely 
false 
a) I seem to get sick a little         
easier than other people 
" " " " 
b) I am as healthy as anybody   
I know 
" " " " 
c) I expect my health to get        
worse 
" " " " 
d) My health is excellent " " " " 
 
SF-36v2 Medical Outcomes Trust and John E. Ware Jr. - All Rights Reserved 
 
+
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Appendix C:  Self Care Resource Inventory 
Directions: We are interested in the things or “resources” that may be 
helpful to you in dealing with your illness. First, you are asked to rate each 
resource in terms of how much you need it to help you deal with your 
illness and get better. Second, you are asked to rate each resource in 
terms of how much is available to you. Rate your responses for each from 
0 (none) to 4 ( a lot). Circle the number that best represents how you feel 
as you rate each “resource”. There are no right or wrong answers, so 
complete each item as honestly as you can. Be sure that you circle one 
number in each column on every line.
 
 
Amount I 
Need  
 
None          A  
Lot 
Amount I Have
 
 
None          A  
Lot
1. Emotional support from my family 0   1   2   3   4  0   1   2   3   4  
2. Control over my daily activities 0   1   2   3   4  0   1   2   3   4  
3. Information about my illness and treatment 0   1   2   3   4  0   1   2   3   4  
4. Spiritual strength 0   1   2   3   4  0   1   2   3   4  
5. Someone who can make me laugh 0   1   2   3   4  0   1   2   3   4  
6. Feeling good about myself 0   1   2   3   4  0   1   2   3   4  
7. A good relationship with my health care providers 0   1   2   3   4  0   1   2   3   4  
8. Control over my plan of care 0   1   2   3   4  0   1   2   3   4  
9. Having the skill to do the things that will help me 
get better 
0   1   2   3   4  0   1   2   3   4  
10. Setting goals that I can reach 0   1   2   3   4  0   1   2   3   4  
11. Assistance with my usual family responsibilities 0   1   2   3   4  0   1   2   3   4  
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Amount I 
Need  
 
None          A  
Lot 
Amount I Have
 
 
None          A  
Lot
12. The will to live 0   1   2   3   4  0   1   2   3   4  
13. Being able to laugh 0   1   2   3   4  0   1   2   3   4  
14. Financial resources to take care of myself 0   1   2   3   4  0   1   2   3   4  
15. Emotional support from friends 0   1   2   3   4  0   1   2   3   4  
16. Someone to help me do things that I cannot do 
myself 
0   1   2   3   4  0   1   2   3   4  
17. Feeling that my life has meaning 0   1   2   3   4  0   1   2   3   4  
18. Someone to teach me how to care for myself 0   1   2   3   4  0   1   2   3   4  
19. Emotional strength 0   1   2   3   4  0   1   2   3   4  
20. Assistance so I can do my work or usual 
activities 
0   1   2   3   4  0   1   2   3   4  
21. A positive view of myself 0   1   2   3   4  0   1   2   3   4  
22. Good personal appearance 0   1   2   3   4  0   1   2   3   4  
23. Knowing others respect me 0   1   2   3   4  0   1   2   3   4  
24. Reaching goals that I set 0   1   2   3   4  0   1   2   3   4  
25. Knowing how to care for myself 0   1   2   3   4  0   1   2   3   4  
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Amount I 
Need  
 
None          A  
Lot 
Amount I Have
 
 
None          A  
Lot
26. Hope for the future 0   1   2   3   4  0   1   2   3   4  
27. An intimate relationship 0   1   2   3   4  0   1   2   3   4  
28. Energy to do activities 0   1   2   3   4  0   1   2   3   4  
29. Willingness to try new roles 0   1   2   3   4  0   1   2   3   4  
30. Desire to set new goals 0   1   2   3   4  0   1   2   3   4  
31. Someone to confide in 0   1   2   3   4  0   1   2   3   4  
32. Prayer 0   1   2   3   4  0   1   2   3   4  
33. Financial resources to take care of my family 0   1   2   3   4  0   1   2   3   4  
34. A close friend 0   1   2   3   4  0   1   2   3   4  
35. Religious activities 0   1   2   3   4  0   1   2   3   4  
Copyright 1994 Linda S. Baas 
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Appendix D: Permission letter to use Minnesota Living with Heart Failure Questionnaire   
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Appendix E: Permission letter to use Short Form-36 version 2 
 
Subj. Single User Non-Commercial License Agreement Date: 11/19/2001 1 :06:06 PM Eastern Standard Time  
From: kmcbride@qualitymetric.com (Kathy M. McBride) To: jlbphd@aol.com  
 
Monday, November 19, 2001  
 
Janet Bischof Student  
Duquesne Uni\ersity  
80 Fernwood AVenue  
Wheeling, WV 26003  
United States  
 
Regarding your project: Dissertation document for Ph. D. in Nursing schoolwork   
 
Dear Janet:  
 
I am pleased to grant you permission to use and reproduce the U.S. English versions of the SF-36v2(r) Health 
Survey(s), subject to the following terms and conditions:  
 
Permission to use the U.S. English \versions of the SF-36v2(r) is granted royalty free for individual research and 
institutional non-commercial  
use. This permission does not extend to reproduction or transmission of the instrument(s), scoring algorithm(s), 
and/or normative data on a computer network, Intranet, Internet ser\er. It also does not extend to  
those wishing to re-sell, sub license, or otherwise distribute the survey forms or scoring algorithms as part of their 
product or service offerings (whether or not a fee is charged). Such use requires a special license,  
and interested parties should write license@qmetric.com for more information  
 
This permission to use is for the U.S. English \version only. Information and permission to use the non-U.S. English 
translations of the SF-36v2(r) can be obtained from the International Quality of Life Assessment (IQOLA) project. 
Please direct your inquiries to info@iqola.org.  
 
Please know that we ha\-e added you to our mailing list and encourage you to ...;sit our websites, WI.Wv'.qmetric.com and 
www.amlhealthy .com, for the most up-to-date infonnation on our scientific products and services.  
 
Sincerely,  
 
John E. Ware, Jr., Ph.D. Chief Executive Officer QualityMetric Incorporated  
 
Executive Director, Health Assessment Lab  
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Appendix F: Permission letter to use the Self Care Resource Inventory 
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Appendix G: Patient Demographic Questionnaire 
 
 Patient Demographic Questionnaire 
  
Study ID # ___________ 
 
Please verbally complete the following questions: 
 
Full name ________________________________________________________ 
 
Where is this interview taking place ____________________________________ 
 
Today’s Date: Month ______________ Day _____________ Year ____________ 
 
Who is currently the president of the United States? _________________________ 
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 Patient Demographic Questionnaire   Study ID # ____________   
 
Please answer the following questions to the best of your ability: 
 
1. Age : __________ years 
 
2. Gender (check one) 
_____ Male 
_____ Female 
 
3. Education (check one) 
_____ less than 8 years of school 
_____ less than 12 years of high school 
_____ graduated high school 
_____ vocational/tech school education 
_____ graduated from a 2 year college 
_____ graduated from a 4 year college 
_____ graduate school 
_____ post graduate classes 
 
4. Race/Ethnicity (check one) 
_____ Asian 
_____ Black - African American 
_____ Hispanic 
_____ White 
_____ Other __________________ 
 
5. Marital Status (check one) 
_____ Single 
_____ Living with partner 
_____ Married 
_____ Married living apart 
_____ Widow/Widower 
_____ Divorced 
_____ Separated 
 
6. Number of Children _________         
 
_____ Number of Females _____ Number of Males 
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          Study ID #__________ 
7. Please answer all medical conditions that apply to you 
 No Yes If Yes, Number of years 
COPD (Chronic Obstructive Lung Disease)    
Lung problems    
Emphysema    
Diabetes    
CVA (Stroke)    
Hypertension (high blood presssure)    
Cardiomyopathy    
MI (heart attack)    
Angina    
CAD (coronary artery disease)    
Dysrhythmias    
Artrial Fib/Flutter (irregular heart rate)    
Congenital Heart Defect    
Rheumatic Heart Disease    
Valvular Heart Disease    
Other    
 
8. How long have you known of your Heart Failure diagnosis? ___________years 
 
9. In the past 12 months, how many times have  you stayed in the hospital 
overnight?_________ 
Specifically for Heart Failure? ___________ 
 
Number of days in hospital with last hospital admission? ____________ 
 
10. How many Emergency room visits for Heart Failure in the past 12 months 
have you had?  ___________ 
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         Study ID # ____________ 
11. How many physician or clinic visits for HF have you had in the past 12 
months_____ 
How many phone calls for problems?____________ 
 
12. For all your health care needs, how many physicians do you see? 
_____ 1 
_____ 2 
_____ 3 
_____ 4 
_____ 5 
_____ more than 5 
 
13. Which person helps you at home the most to manage with your Heart Failure?  
 
 
14. Who do you call first if you develop problems with your Heart Failure (for example, 
increased weight gain, shortness of breath, swelling of feet or legs)? _______________ 
 
15. Would you please list the medications you are currently taking? 
Medication Dosage 
(ie mg, units, 
grams) 
Frequency 
 
How many 
times a day 
Do you take the 
medication as the 
physician ordered?  
Yes or No 
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Medication Dosage 
(ie mg, units, 
grams) 
Frequency 
 
How many 
times a day 
Do you take the 
medication as the 
physician ordered?  
Yes or No 
    
    
    
    
               
16. When you have an appointment for your heart failure - which health care 
personnel do you routinely see? (Check all that apply) 
_____ Cardiac rehab personnel 
  _____ Cardiologist  
_____ Dietician 
_____ Nurse Practitioner 
_____ Occupational Therapist 
_____ Pharmacist  
_____ Physical therapist   
_____ Physician  
_____ Physician Assistant 
_____ Psychologist 
_____ Registered Nurse 
_____ Social Worker 
 
17. Where were you first diagnosed with Heart Failure? 
_____ Hospital 
_____ Physician office 
_____ Clinic office 
_____ Emergency Room 
 
18. How many miles do you travel to keep this appointment? 
__________________ 
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19. How do you define or describe heart failure? 
 
 
 
20. Did you ever not receive a medication or treatment because your insurance 
would not pay for it?    _____ Yes     _____ No 
What was it? 
 
21. What does heart failure mean to you? 
 
 
 
22. Is there any other information you consider important? 
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Appendix H: Pilot Study Letter and Questions 
 
80 Fernwood Avenue 
Wheeling, WV 26003 
June 6, 2003 
 
 This research is in conjunction with Janet Bischof’s dissertation at Duquesne University entitled 
“A comparison of the Adult Heart Failure Patient’s Quality of Life when managed in different medical 
settings: A Heart Failure Clinic and a Cardiology Practice”. I have selected the four surveys to be used in 
my research and have some questions about their use in my research. 
 
 Participation in the testing of these surveys will take no more than an hour of your time. There is 
no risk associated with participation and you are assured confidentiality. Your return of the completed 
survey indicates your consent to participate in this pilot study. 
 
 Enclosed you will find a copy of the surveys to be reviewed. These surveys are intended to be 
completed by patients who have a diagnosis of heart failure. I am not interested in the content of the 
answers. I am interested in the process and ease of completing the surveys. Please read the following 
instructions prior to completing the surveys. 
 
 Instructions: 
1. When you are ready to start completing the questionnaire please mark the time that you start. 
For example 10:15 am 
2. Answer the questions on all pages. Again your answers are not as important as your ease in 
completing the questions. 
3. If you have concerns about words used, instructions, or unclear questions - please feel free to 
write on the surveys and indicate your problems. 
4. When you are finished with the survey indicate the time you finished. For example 10:45 am. 
5. Then, please take a few minutes to complete the questions about the “look” of the surveys. 
 
 When you have completed the survey and questions - please return them to Leah Martin or by 
mail using the enclosed self-addressed stamped envelope. 
 
 Your review of these surveys will assist in my research efforts and allow the patients that 
participate in this research to have clear, easy to follow surveys to complete. Your participation is greatly 
appreciated. 
 
Sincerely 
Janet Bischof RN, MS, CCRN, CNA 
Doctoral Student Duquesne University 
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Pilot Study Questions 
 
1. Age of reviewer ______________ years 
 
2. Time you started reviewing the surveys ____________________ 
 
3. Time you completed reviewing the surveys __________________ 
 
4. Were you able to read the size of print without problem? _____ Yes _____No 
      Comments: 
 
 
 
5. Did shading or coloring of every other question make it easier to read and answer the       
questions? _____ Yes _____ No 
     Comments: 
 
 
 
6. Is the white paper the surveys are printed on make it easy to read?   
      _____ Yes _____ No 
      Comments: 
 
 
 
7. Does having the pages printed front and back make it harder to complete the       
questions? _____ Yes _____ No 
     Comments: 
 
 
Reminder: You may write on the surveys if there are particular questions you did not 
understand or instructions that were unclear. 
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Appendix I: Medical Chart Questionnaire 
 
 MEDICAL CHART REVIEW (to be completed by the researcher) 
 
Study ID # ____________ 
 
EF% 
initial % ________________ Date ___________ 
current % _______________Date ___________ 
Echo Results: 
 
 
 
Cardiac Cath results: 
 
 
 
 
NYHA Classification   
_____ I 
_____ II 
_____ III 
_____ IV 
HF type 
_____ Systolic 
_____ Diastolic 
_____ Combination 
_____ Undetermined 
 
# of documented visits in past 12 months ___________________ 
number of calls ______________ 
 
Medical profile from chart 
Medication Dosage 
(ie mg, units, grams) 
Frequency 
How many times a day 
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Medication Dosage 
(ie mg, units, grams) 
Frequency 
How many times a day 
   
   
   
   
   
   
   
   
   
   
   
   
 
Past medical History 
 Yes No Number of years 
COPD    
Lung problems    
Emphysema    
Diabetes    
CVA (Stroke)    
Hypertension (high blood presssure)    
Cardiomyopathy    
MI (heart attack)    
Angina    
CAD (coronary artery disease)    
Dysrhythmias    
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 Yes No Number of years 
Artrial Fib/Flutter (irregular heart rate)    
    
Congenital Heart Defect    
Rheumatic Heart Disease    
Valvular Heart Disease    
Other    
 
If LBBB - pacemaker? 
 
 
Date first seem in clinic or physician office _________________ 
 
Date interviewed __________________ 
 
Primary physician ________________ 
 
Are you using a HF procotol or guideline 
 ____ clinic specific 
 ____ office specific 
 ____ ACC guidelines 
 ____ HSA guidelines 
 
 
Failed treatments: 
 
 
Insurance company: 
 
 
Referral to clinic or physician office from ________________________ 
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Appendix J:  Sample Size Comparisons from Previous Heart Failure Studies 
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Appendix K: Patient Information Brochure 
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Appendix L: Duquesne University IRB Approval Letter 
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Appendix M: NIH Education Protection of Human Subjects 
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Appendix N: West Penn Allegheny Health System IRB Approval Letter 
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Appendix O: West Penn Allegheny Health System Education Protection of Human 
Subjects 
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Appendix P: Informed Consent Documents 
 
CONSENTTO PARTICIPATE 
IN A RESEARCH STUDY 
 
 
Duquesne University 
School of Nursing 
Title:  A comparison of the Adult Heart Failure Patient’s Quality of Life when managed in 
different medical settings: A Heart Failure Clinic and a Physician Practice 
 
Principal Investigator: 
Janet Bischof RN, MS, CCRN, CNA 
 Student, Duquesne University School of Nursing 
 80 Fernwood Avenue 
 Wheeling, WV 26003 
 Home (304)242-8453 
 
Advisor: 
Dr. Kathleen Sekula PhD, APRN 
 628 College Hall 
 School of Nursing 
 Duquesne University 
 Pittsburgh PA 15282 
 Work (412) 396-4865 
 
Source of Support:  
This study is being performed as partial fulfillment of the Requirements for the doctoral degree in Nursing at 
Duquesne University, Pittsburgh, PA 
 
Purpose: 
You are being asked to participate in a research project that seeks to study quality of life measures in the 
heart failure group. The study is trying to determine how you think heart failure has changed your daily life. 
You will be asked to answer paper and pencil surveys that will take approximately 40 minutes of your time to 
complete. 
     
Subjects: 
You are being invited to take part in this research study because you have already been diagnosed with 
heart failure. People invited to join in this study must be over the age of 18, currently receiving treatment for 
heart failure, and have the ability to read and write English. 
 
The investigators are committed to comply with the basic principles of the NIH guidelines on inclusion of 
women and minorities in research, and will make every effort to enroll subjects into the study from both 
sexes, all minority groups, and age levels. 
 
 
Procedures to be Performed: 
If you decide to take part in this research study, you will be asked to complete 4 written questionnaires: The 
Minnesota Living with Health Failure Questionnaire, the Short Form-36 version 2 survey, the Self Care 
Resource Inventory questionnaire, and a general questionnaire about you personally. Confidentiality will be 
maintained and at no time will the participants names be recorded. 
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Risks: 
The risks of this study involve sharing of personal medical and social information. There are no physical 
risks involved. 
You  will be promptly notified, if during this research study, any new information develops which may cause 
you to change your mind about continuing to participate. 
 
Benefits: 
The benefits of this study involve the ability to share collected information with other health care workers to 
better provide care to heart failure patients. 
 
Alternate Procedures: 
What treatments or procedures are available if I decide not to participate in this study: 
If you decide not to participate in this study, you will continue to receive heart failure medical care in your 
current setting. 
 
Costs: 
Neither you nor your insurance provider will be charge for the costs of any portion of this study. 
 
Payment: 
There will be no monetary compensation for completing the surveys this research study. I have been fully 
informed by the researcher and I understand fully, that in the event of any physical injury, or injuries resulting 
from research procedure or protocols to which I have voluntarily and knowingly agreed to participate in, that 
no monetary compensation or free medical treatment will be made available to me by Allegheny General 
Hospital or Allegheny-Singer Research Institute. 
 
Confidentiality: 
Any information about you obtained from this research will be kept as confidential (private) as possible. All 
record related to your involvement in this research will be stored in a locked file cabinet at the researcher’s 
home. Your identify on these records will be indicated by a case number rather than by your name, and the 
information linking these case numbers will be kept separate from the research records. You will not be 
identified by name in any publication of the research results. 
 
In 1996 the government passed a law known as The Health Insurance Portability and Accountability act 
(HIPAA), Public Law 104-191. This privacy law, among other things will improve how your health care 
information is protected and kept confidential when it is used ot disclosed with others. This includes both 
your medical records and insurance information as well as other personal health information. This consent 
form describes to you how information about you may be used or disclosed (released) if you are in a 
research study. It is import that you read this carefully. 
 
In order to participate in this research study you must permit (allow) certain research records to be made 
about you in addition to the usual records the hospital and doctors create about your medical treatment. 
These research records will contain private medical and other information, which is protected by law. The 
researchers will only create the minimum amount of research records necessary to carry out the research. 
 
 
 Types of research records that may be shared/copied is: 
          Tissue Samples 
    X    Medical Records - a review of your medical record in the clinic/office 
          Lab Results 
          Other (specify) 
 
In addition to using these research records to carry out the research and, perhaps, to treat you, the 
researchers will share portions of these research records to third parties involved in the research study. The 
third parties, who receive research information, may further share the information about you in accordance 
  
149
with their policies, practices, and what the law requires. However, some third parties, (such as the Sponsor) 
may not need to follow theh privacy law. To the best of our knowledge, a complete and accurate description 
of who the third parties are and how they will use or disclose the information are as follows: 
 
 Third Party  Purpose 
Allegheny-Singer Research Institute 
Duquesne University 
May share this signed consent form and records that 
identify you for purposes related to this research and for 
publication. 
 
 
The release of information described above will be the minimum necessary to abide by the law complete the 
research, and perhaps, publish the research. 
 
Unlike your medical records, you will not have access to research records made about you during the study. 
However, these will be available at the end of the study. Although every effort will be made to keep research 
records about you private, complete confidentiality cannot be guaranteed. Such research records may be 
subject to subpoena or court order. The researcher has set up safeguards to keep private information about 
you confidential. 
 
There is no expiration for this Authorization unless you revoke (cancel) it. You may revoke this Authorization 
by writing to the Principal Investigator. If you revoke your Authorization, you will also be removed from the 
study. Revoking your Authorization only affects the use and sharing of your information after the written 
request is received. Any information obtained prior to receiving the written request may be used to maintain 
integrity of the study (for example account for reporting of side effect, sending information to the FDA for 
studies it regulates. 
 
This research will involve the recording of current medical information from your current medical record. The 
information will be recorded will be limited to the information concerning the purpose of this study. Your 
identify on these records will be indicated by a case number rather than by your name, and the information 
linking these case numbers will be kept separate from the research records. You will not be identified by 
name in any publication of the research results. 
 
If you choose not to sign this Authorization, you will not e permitted to participate in this research study. In 
order to participate in this study, you must agree to the use and disclosure of your information with the 
groups above. Upon completion of the study or if you withdraw from the study at any time, the research 
records about you will be kept by the researcher(s) and all of the information provided above will continue to 
apply to your research records. 
 
You give permission that your research records can be used and disclosed as described. 
 
Voluntary Participation 
Your participation in this research study is completely voluntary. Whether or not you provide your consent for 
participation in this research study will have no affect on your current or future relationship with your health 
care provider or health care insurance provider. 
 
Inquires 
If you have any questions or concerns regarding the research study, you may contact the principal 
investigator as listed on page 1 or the Allegheny Singer Research Institute at (412) 359-3156. 
 
Right to Withdraw: 
You are under no obligation to participate in this research study. You are free to withdraw your consent to 
participate at any time. To formally withdraw your consent for participation in this research study you may 
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stop completing the questionnaires and document withdrawal from study on the last page. Your decision to 
withdraw will have no affect on your current or future relationship with your current medical provider or 
insurance provider. 
 
Summary of Results: 
A one page summary of results of this research study will be supplied to you at no cost, upon request. 
 
Voluntary Consent: 
I have read the above statements and understand what is being requested of me. I also understand that my 
participation is voluntary and that I am free to withdraw my consent at any time, for any reason. All of my 
current questions have been answered. I understand that I am encouraged to ask questions about any 
aspect of this research study during the course of this study, and that such future questions will be answered 
by the researchers as listed on the first page of this form. 
 
By signing this form, I agree that I am willing to participate in the research study. A copy of this consent form 
will be given to me. 
 
I understand that should I have any further questions about my participation in this study, I may call Dr. Paul 
Richer, Chair of the Duquense University Institutional Review Board (412-396-6326) or the Human Subject 
Protection Advocate of the IRB Office, University of Pittsburgh (412-578-8570). 
 
 
 
_____________________________  ______________ 
 
Participant’s Signature    Date 
 
I certify that I have explained the nature and purpose of this research study to the above-named individual 
and I have discussed the potential benefits and possible risks of study participation. Any questions the 
individual has about this study have been answered, and we will always be available to address future 
questions as they arise. 
 
 
_____________________________   
 
Printed name of Person Obtaining Consent Role in Research Study 
 
_____________________________  _______________ 
 
Signature of Person Obtaining Consent  Date 
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